In situ adjustable optical mask

Information

  • Patent Grant
  • 9204962
  • Patent Number
    9,204,962
  • Date Filed
    Wednesday, March 13, 2013
    11 years ago
  • Date Issued
    Tuesday, December 8, 2015
    9 years ago
Abstract
Implantable corneal and intraocular implants such as a mask are provided. The mask can improve the vision of a patient, such as by being configured to increase the depth of focus of an eye of a patient. The mask can include an aperture configured to transmit along an optical axis substantially all visible incident light. The mask can further include a transition portion that surrounds at least a portion of the aperture. This portion can be configured to switch from one level of opacity to another level of opacity through the use of a controllably variable absorbance feature such as a switchable photochromic chromophore within a polymer matrix.
Description
BACKGROUND OF THE INVENTION

1. Field


This application relates generally to the field of ophthalmic devices. More particularly, this application is directed to corneal masks and intraocular implants, and methods of making the same.


2. Description of the Related Art


The human eye functions to provide vision by transmitting and focusing light through a clear outer portion called the cornea, and further refining the focus of the image onto a retina by way of a crystalline lens. The quality of the focused image depends on many factors including the size and shape of the eye, and the transparency of the cornea and the lens.


The optical power of the eye is determined by the optical power of the cornea and the crystalline lens. In a normal, healthy eye, sharp images of distant objects are formed on the retina (emmetropia). In many eyes, images of distant objects are either formed in front of the retina because the eye is abnormally long or the cornea is abnormally steep (myopia), or formed in back of the retina because the eye is abnormally short or the cornea is abnormally flat (hyperopia). The cornea also can be asymmetric or toric, resulting in an uncompensated cylindrical refractive error referred to as corneal astigmatism.


A normally functioning human eye is capable of selectively focusing on either near or far objects through a process known as accommodation. Accommodation is achieved by inducing deformation in a lens located inside the eye, which is referred to as the crystalline lens. Such deformation is induced by muscles called ciliary muscles. In most individuals, the ability to accommodate diminishes with age and these individuals cannot see up close without vision correction. If far vision also is deficient, such individuals are usually prescribed bifocal lenses.


SUMMARY OF THE INVENTION

For purposes of summarizing the disclosure, certain aspects, advantages and novel features of the invention have been described herein. It is to be understood that not necessarily all such advantages can be achieved in accordance with any particular embodiment of the inventions disclosed herein. Thus, the inventions disclosed herein can be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other advantages as can be taught or suggested herein.


A first aspect of this application is directed toward an ophthalmic device comprising a mask configured to transmit substantially all visible light along an optical axis of the eye, the mask further comprising a transition portion configured to switch between at least a first degree of opacity and a second degree of opacity; and wherein the transition portion comprises a photochromic chromophore within a polymer matrix.


The mask may include an aperture configured to transmit substantially all visible light along the optical axis of the eye.


The mask may include a plurality of holes extending at least partially between an anterior surface of the mask and a posterior surface of the mask.


An intraocular lens may be coupled with the mask.


The first degree of opacity may allow transmission of substantially all visible light through the transition portion of the mask.


The second degree of opacity may prevent transmission of substantially all visible light through the transition portion of the mask.


The transition portion of the mask may comprise at least 50% of the total mask.


The transition portion may be configured to switch between a first degree of opacity and a second degree of opacity via application of both light and heat.


The polymer matrix may have a glass transition temperature of between 30-150° C.


The photochromic chromophore may comprise spiropyran.


Another aspect of this application is directed toward a method of switching the opacity of at least a portion of an ophthalmic device. The method includes providing a photochromic polymer mask with a controlled glass transition temperature, inserting the mask into an eye, and applying light and heat to the mask.


The heat may be applied via a laser, via ultrasonic energy or other energy modality for elevating the temperature of the mask.


A microscope can be used to monitor the photochromic polymer mask.


The glass transition temperature may be controlled by altering the chain length of the polymer.


The glass transition temperature may be controlled by altering the cross-link density of the polymer.


Another aspect of this application is directed toward a method of forming a mask portion. The mask includes a transition portion configured to switch between a first degree of opacity and a second degree of opacity and an aperture in the mask portion, the aperture configured to transmit substantially all visible light along an optical axis of an eye.


The method may include forming a plurality of holes in the mask portion, the plurality of holes extending at least partially between an anterior surface and a posterior surface of the mask.


The method may include coupling the mask portion with an intraocular lens.


The transition portion may include a photochromic chromophore contained within a polymer matrix.





BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments will be described hereinafter with reference to the accompanying drawings. These embodiments are illustrated and described by example only, and are not intended to limit the scope of the disclosure. In the drawings, similar elements have similar reference numerals.



FIGS. 1A and 1B depict a conventional intraocular lens.



FIG. 2A is a perspective view of one embodiment of a mask.



FIG. 2B is a perspective view of another embodiment of a mask.



FIG. 3A depicts a top view of another embodiment of a mask configured to increase depth of focus.



FIG. 3B depicts an enlarged view of a portion of the view of 3B.



FIG. 4 is a cross-sectional view of the mask of FIG. 3B taken along the section plane 4-4.



FIG. 5 is a graphical representation of one arrangement of holes of a plurality of holes that can be formed in an ophthalmic device.



FIGS. 6A and 6B depict an embodiment of a mask that switches between one level of opacity and another level of opacity.



FIG. 7 is a flowchart that depicts one embodiment of a method for switching the opacity of a transition portion of a mask.



FIGS. 8A-8F depict multiple embodiments of various geometries of the transition portions of a mask.



FIG. 9 depicts one embodiment of the synthesis of a photochromic monomer.



FIG. 10 depicts one embodiment of the synthesis of a photochromic polymer from the monomer of FIG. 9.



FIG. 11 depicts one embodiment of a general formula for a photochromic polymer.



FIG. 12 depicts one embodiment of a side-chain crystallizable polymer.





DETAILED DESCRIPTION

This application is directed to ocular devices and implants (e.g., masks) for improving the depth of focus of an eye of a patient and methods and apparatuses for making such ocular devices. The masks generally employ small-aperture vision correction methods to enhance depth of focus in a presbyopic eye thereby providing functional near vision. The masks can be applied to the eye in any manner and in any anterior-posterior location along the optical path, e.g., as an implant in the cornea (sometimes referred to as a “corneal inlay”). The masks can also be embodied in or combined with lenses and applied in other regions of the eye, e.g., as or in combination with contact lenses or intraocular lenses (IOL).


The ocular devices and masks described herein can be applied to masks and/or combined with features described in U.S. Patent Publication No. 2011/0040376, filed Aug. 13, 2010, entitled “MASKED INTRAOCULAR IMPLANTS AND LENSES,” and International Patent Publication No. WO 2011/020074, filed Aug. 13, 2010, entitled “CORNEAL INLAY WITH NUTRIENT TRANSPORT STRUCTURES, hereby incorporated by reference in their entirety.”


A conventional intraocular lens 1000 is illustrated in FIGS. 1A-B. The cross-sectional thickness of the lens body 1002 is generally dependent on the optical power of the intraocular lens 1000 and the material of the lens body 1002. In particular, the central region of the lens body 1002 is generally the thickest section of the intraocular lens 1000 with a central region cross-sectional thickness 1006. Methods for reducing the thickness of the intraocular lens are described in U.S. Pub. No. 2011/0040376, filed Aug. 13, 2010, hereby incorporated by reference in its entirety.


The intraocular lens and/or the lens body can be made from one or more materials. In certain embodiments, the intraocular lens and/or the lens body can comprise polymers (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic copolymers, polystyrene, PVC, polysulfone), hydrogels, and silicone).


A variety of variations of masks that can be used alone or positioned on or within the implant body are discussed herein, and also described in U.S. Pat. No. 7,628,810, U.S. Patent Publication No. 2006/0113054, and U.S. Patent Publication No. 2006/0265058, all of which are hereby incorporated by reference in their entirety. FIG. 2A illustrates one embodiment of a mask 2034a. The mask 2034a can include an annular region 2036a surrounding an aperture 2038a substantially centrally located on the mask 2034a. The aperture 2038a can be generally located around a central axis 2039a, referred to herein as the optical axis of the mask 2034a. The aperture 2038a can be in the shape of a circle. FIG. 2B illustrates another embodiment of a mask 2034b similar to the mask 2034a illustrated in FIG. 2A. The annular region 2036a of the mask 2034a of FIG. 2A has a curvature from the outer periphery to the inner periphery of the annular region 2036a, such that the annular region 2036a substantially conforms to the surface of a geometry of rotation, such as a sphere. The annular region 2036b of the mask 2034b of FIG. 2B is substantially flat.


The mask can have a constant thickness. However, in some embodiments, the thickness of the mask can vary between the inner periphery (near the aperture 2038a,b) and the outer periphery.


The mask can have dimensions configured to improve a patient's vision. For example, if the mask is embedded within the implant body, the thickness of the mask can vary depending on the location of the mask relative to the implant body. For example, the mask can have a thickness greater than zero and less than the thickness of the implant body. Alternatively, if the mask is coupled to a surface of the implant body, the mask can preferably have a thickness no greater than necessary to have desired opacity so that the mask does not add additional thickness to the intraocular lens. In certain embodiments, the mask has a thickness of greater than zero and less than about 0.5 mm. In some embodiments, the mask has a thickness of at least about 0.25 mm and/or less than or equal to about 0.3 mm. In some embodiments, the mask has a thickness of at least 0.005 mm and/or less than or equal to about 0.015 mm. In one embodiment, the mask has a thickness of about 0.25 mm. If the mask is on or near the surface of a transition zone, as described in U.S. Pub. No. 2011/0040376, filed Aug. 13, 2010 and hereby incorporated by reference in its entirety, the mask can have a shape similar or the same as the transition zone.


The annular region 2036a,b can be at least partially opaque or can be completely opaque to visible light. The degree of opacity of the annular region 2036a,b prevents at least some or substantially all light from being transmitted through the mask 2034a,b. Generally, transmission of light through the annular region will be no more than about 5%, often no more than about 3% and in some applications, no more than about 1%. Opacity of the annular region 2036a,b can be achieved in any of several different ways.


For example, in one embodiment, the material used to make mask 2034a,b can be naturally opaque. Alternatively, the material used to make the mask 2034a,b can be substantially clear, but treated with a dye or other pigmentation agent to render region 2036 substantially or completely opaque. In still another example, the surface of the mask 2034 can be treated physically or chemically (such as by etching) to alter the refractive and transmissive properties of the mask 2034a,b and make it less transmissive to light.


The material of the mask 2034a,b can be, for example, any of a variety of polymeric materials. Where the mask 2034a,b is applied to or fixed within the intraocular implant, the material of the mask 2034 should be biocompatible. Examples of suitable materials for the mask 2034a,b include the preferred PVDF, other suitable polymers or co-polymers, such as hydrogels, or fibrous materials, such as a Dacron mesh.


In additional embodiments, a photochromic material can be used as the mask or as a variable transmission zone in addition to a non-photochromic or non-variable transmission zone of the mask. Under bright light conditions, the photochromic material can darken thereby creating a mask (having a transmission aperture) and enhancing near vision. Under dim light conditions, the photochromic material lightens, which allows more light to pass through to the retina. In certain embodiments, under dim light conditions, the photochromic material lightens to expose an optic of the intraocular implant. Further photochromic material details are disclosed in U.S. patent application Ser. No. 13/691,625, filed Nov. 30, 2012, which is hereby incorporated by reference in its entirety.


The mask can have different degrees of opacity. For example, the mask can block substantially all of visible light or can block a portion of visible light. The opacity of the mask can also vary in different regions of the mask. In certain embodiments, the opacity of the outer edge and/or the inner edge of the mask is less than the central region of the mask. The opacity in different regions can transition abruptly or have a gradient transition. Additional examples of opacity transitions can be found in U.S. Pat. Nos. 5,662,706, 5,905,561 and 5,965,330, all of which are hereby incorporated by reference in their entirety.


Further mask details are disclosed in U.S. Pat. No. 4,976,732, issued Dec. 11, 1990, U.S. Pat. No. 7,628,810, issued Dec. 8, 2009, and in U.S. patent application Ser. No. 10/854,032, filed May 26, 2004, all of which are hereby incorporated by reference in their entirety.


An advantage to embodiments that include a mask with an aperture (e.g., pin-hole aperture) described herein over multifocal IOLs, contact lenses, or refractive treatments of the cornea is that all of these latter approaches divide the available light coming through the aperture into two or more foci while a mask approach has a single focus (monofocal). This limitation forces designers of multifocal optics to choose how much of the light is directed to each focal point, and to deal with the effects of the unfocused light that is always present in any image. In order to maximize acuity at the important distances of infinity (>6M) and 40 cm (normal reading distance), it is typical to provide little or no light focused at an intermediate distance, and as a result, visual acuity at these distances is poor. With a mask that includes an aperture to increase depth-of-focus, however, the intermediate vision of presbyopic patients is improved significantly. Indeed, the defocus blur with the aperture is less at intermediate distances than at near.



FIGS. 3-4 show another embodiment of a mask 2100 configured to increase depth of focus of an eye of a patient with presbyopia. The mask 2100 is similar to the masks hereinbefore described, except as described differently below. The mask 2100 can be made of the materials discussed herein, including those discussed above. In addition, the mask 2100 can be formed by any suitable process. The mask 2100 is configured to be applied to an IOL.


In one embodiment, the mask 2100 includes a body 2104 that has an anterior surface 2108 and a posterior surface 2112. The body 2104 can be formed of any suitable material, including at least one of an open cell foam material, an expanded solid material, and a substantially opaque material. In one embodiment, the material used to form the body 2104 has relatively high water content. In other embodiments, the materials that can be used to form the body 2104 include polymers (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic copolymers (e.g., hydrophobic or hydrophilic), polystyrene, PVC, polysulfone), hydrogels, silicone, metals, metal alloys, or carbon (e.g., graphene, pure carbon).


In one embodiment, the mask 2100 includes a hole arrangement 2116. The hole arrangement 2116 can comprise a plurality of holes 2120. The holes 2120 are shown on only a portion of the mask 2100, but the holes 2120 preferably are located throughout the body 2104 in one embodiment. The mask 2100 has an outer periphery 2124 that defines an outer edge of the body 2104. In some embodiments, the mask 2100 includes an aperture 2128 at least partially surrounded by the outer periphery 2124 and a non-transmissive or reduced transmissive portion 2132 located between the outer periphery 2124 and the aperture 2128.


Preferably the mask 2100 is symmetrical, e.g., rotationally symmetrical about a mask axis 2136. In one embodiment, the outer periphery 2124 of the mask 2100 is circular. The mask in general has an outer diameter of at least about 3 mm and/or less than about 6 mm. In some embodiments, the mask is circular and has a diameter of at least about 3 mm and/or less than or equal to about 4 mm. In some embodiments, the mask 2100 is circular and has a diameter of about 3.2 mm. In some embodiments, masks that are asymmetrical or that are not symmetrical about a mask axis provide benefits, such as enabling a mask to be located or maintained in a selected position with respect to the anatomy of the eye.


The body 2104 of the mask 2100 can be configured to be coupled with a particular intraocular lens design, either of reduced thickness design or of conventional design. For example, where the mask 2100 is to be coupled with a particular IOL that has curvature, the body 2104 can be provided with a corresponding amount of curvature along the mask axis 2136 that corresponds to the curvature. Likewise, the body 2104 can be provided with corresponding shape to accommodate IOL transition zones. Further details about the reduced thickness design are described in U.S. Pub. No. 2011/0040376, filed Aug. 13, 2010 and hereby incorporated by reference in its entirety.


In one embodiment, one of the anterior surface 2108 and the posterior surface 2112 of the body 2104 is substantially planar. In one planar embodiment, very little or no uniform curvature can be measured across the planar surface. In another embodiment, both of the anterior and posterior surfaces 2108, 2112 are substantially planar. In general, the thickness of the body 2104 of the mask 2100 can be within the range of from greater than zero to about 0.5 mm, about 1 micron to about 40 microns, and often in the range of from about 5 microns to about 20 microns. In some embodiments, the body 2104 of the mask 2100 has a thickness 2138 of at least about 5 microns and/or less than or equal to about 20 microns. In some embodiments, the body 2104 of the mask has a thickness 2138 of at least about 10 microns and/or less than or equal to about 15 microns. In certain embodiments, the thickness 2138 is about 15 microns. In certain embodiments, the thickness 2138 is about 10 microns. In certain embodiments, the thickness 2138 of the mask 2100 is about 5 microns. In another embodiment, the thickness 2138 of the mask 2100 is about 8 microns. In another embodiment, the thickness 2138 of the mask 2100 is about 10 microns.


A substantially planar mask has several advantages over a non-planar mask. For example, a substantially planar mask can be fabricated more easily than one that has to be formed to a particular curvature. In particular, the process steps involved in inducing curvature in the mask 2100 can be eliminated.


The aperture 2128 is configured to transmit substantially all incident light along the mask axis 2136. The non-transmissive portion 2132 surrounds at least a portion of the aperture 2128 and substantially prevents transmission of incident light thereon. As discussed in connection with the above masks, the aperture 2128 can be a through-hole in the body 2104 or a substantially light transmissive (e.g., transparent) portion thereof. The aperture 2128 of the mask 2100 generally is defined within the outer periphery 2124 of the mask 2100. The aperture 2128 can take any of suitable configurations, such as those described above.


In one embodiment, the aperture 2128 is substantially circular and is substantially centered in the mask 2100. The size of the aperture 2128 can be any size that is effective to increase the depth of focus of an eye of a patient with presbyopia. In particular, the size of the aperture 2128 is dependent on the location of the mask within the eye (e.g., distance from the retina). In some embodiments, the aperture 2128 can have a diameter of at least about 0.85 mm and/or less than or equal to about 2.2 mm. In certain embodiments, the diameter of the aperture 2128 is less than about 2 mm. In some embodiments, the diameter of the aperture is at least about 1.1 mm and/or less than or equal to about 1.6 mm. In a further embodiment, the diameter of the aperture is at least about 1.3 mm and/or less than or equal to about 1.4 mm.


In certain embodiments, the aperture 2128 includes an optical power and/or refractive properties. For example, the aperture 2128 can include an optic and can have an optical power (e.g. positive or negative optical power). In certain embodiments, the aperture 2128 can add to the active correction of the intraocular lens.


The non-transmissive portion 2132 is configured to prevent transmission of visible light through the mask 2100. For example, in one embodiment, the non-transmissive portion 2132 prevents transmission of substantially all of at least a portion of the spectrum of the incident visible light. In one embodiment, the non-transmissive portion 2132 is configured to prevent transmission of substantially all visible light, e.g., radiant energy in the electromagnetic spectrum that is visible to the human eye. The non-transmissive portion 2132 can substantially prevent transmission of radiant energy outside the range visible to humans in some embodiments.


As discussed above, preventing transmission of light through the non-transmissive portion 2132 decreases the amount of light that reaches the retina and the fovea that would not converge at the retina and fovea to form a sharp image. As discussed above, the size of the aperture 2128 is such that the light transmitted therethrough generally converges at the retina or fovea. Accordingly, a much sharper image is presented to the retina than would otherwise be the case without the mask 2100.


In one embodiment, the non-transmissive portion 2132 prevents transmission of at least about 90 percent of incident light. In another embodiment, the non-transmissive portion 2132 prevents transmission of at least about 95 percent of all incident light. The non-transmissive portion 2132 of the mask 2100 can be configured to be substantially opaque to prevent the transmission of light.


In some embodiments, the non-transmissive portion 2132 can transmit no more than about 5% of incident visible light. In some embodiments, the non-transmissive portion 2132 can transmit no more than about 3% of incident visible light. In some embodiments, the non-transmissive portion 2132 can transmit no more than about 2% of incident visible light. In one embodiment, at least a portion of the body 2104 is configured to be opaque to more than 99 percent of the light incident thereon.


As discussed above, the non-transmissive portion 2132 can be configured to prevent transmission of light without absorbing the incident light. For example, the mask 2100 could be made reflective or could be made to interact with the light in a more complex manner, as discussed in U.S. Pat. No. 6,554,424, issued Apr. 29, 2003, which is hereby incorporated by reference in its entirety.


As discussed above, the mask 2100 can include a plurality of holes 2120. The lens body can extend at least partially through the holes, thereby creating a bond (e.g. material “bridge”) between the lens body on either side of the mask.


The holes 2120 of the mask 2100 shown in FIG. 3A can be located anywhere on the mask 2100. In some embodiments, substantially all of the holes are in one or more regions of a mask. The holes 2120 of FIG. 3A extend at least partially between the anterior surface 2108 and the posterior surface 2112 of the mask 2100. In one embodiment, each of the holes 2120 includes a hole entrance 2160 and a hole exit 2164. The hole entrance 2160 is located adjacent to the anterior surface 2108 of the mask 2100. The hole exit 2164 is located adjacent to the posterior surface 2112 of the mask 2100. In one embodiment, each of the holes 2120 extends the entire distance between the anterior surface 2108 and the posterior surface 2112 of the mask 2100. Further details about possible hole patterns are described in WO 2011/020074, filed Aug. 13, 2010, incorporated by reference above.


In some embodiments, the mask 2100 can include an annular region near the outer periphery 2124 of the mask having no holes. In certain embodiments, there are no holes within 0.1 mm of the outer periphery 2124 of the mask 2100.


In some embodiments, the mask can include an annular region around the inner periphery of the mask having no holes. In certain embodiments, there are no holes within 0.1 mm of the aperture 2128.


As shown in FIG. 5, the mask 2100 can include a plurality of holes 2120. In some embodiments, the holes 2120 each have a same diameter. In certain embodiments, the holes 2120 can include one or more different diameters. In some embodiments, the diameter of any single hole 2120 is at least about 0.01 mm and/or less than or equal to about 0.02 mm. In some embodiments, the diameter of the holes 2120 can include one or more of the following hole diameters: 0.010 mm, 0.013 mm, 0.016 mm, and/or 0.019 mm.


In some embodiments, the holes are interspersed at irregular locations throughout at least a portion of the mask 2100. In some embodiments, holes of different diameters are evenly interspersed throughout at least a portion of the mask 2100. For example, the mask 2100 can include a plurality of non-overlapping hole regions. The sum of the surface area of the plurality of non-overlapping hole regions can equal to total surface area of the entire hole region of the mask. Each region of the plurality of regions can include a number of holes, each of the holes having a different diameter. The number of holes in each region can equal the number of different hole sizes in the entire hole region.


In some embodiments, there are at least about 1000 holes and/or less than or equal to about 2000 holes. In some embodiments, there are at least about 1000 holes and/or less than or equal to about 1100 holes. In some embodiments, there are about 1040 holes. In some embodiments, there are an equal number of holes of each diameter. In some embodiments, the number of holes having each diameter is different.



FIG. 6A-6B depicts one embodiment of a switchable mask where at least a portion of the mask, hereby referred to as the transition portion, is configured to switch between different levels of opacity to allow different amounts of light to pass through the mask. For example, the transition portion can switch between lower degrees of opacity 3000 to higher degrees of opacity 3002. In this illustrative embodiment, the mask contains photochromic chromophores within a polymer matrix 3004. Although initially substantially colorless, when the photochromic chromophores are allowed to freely rotate and are further exposed to certain activating wavelengths of light, the molecules will rotate into a conformation that absorbs some amount of visible light. However, when the activating light source is removed, the molecules will relax and return to a substantially colorless state. It is particularly advantageous to lock these molecules into one state or another, to prolong the visible light blocking aspect of the molecules. Further, it is advantageous to be able to controllably switch the chromophores between a locked colorless state, wherein visible light can be freely transmitted, to a locked state that absorbs visible light and back again.


In certain embodiments, the free rotation of the photochromic chromophores can be prevented by using particular mask materials such as a photochromic polymer, wherein photochromic chromophores are contained within a polymer matrix. To further control the rotation of the photochromic chromophores, such a polymer matrix can have a controlled glass transition temperature (Tg), such that when heat is applied to the polymer matrix, the matrix undergoes a glass transition from a brittle to a more molten or rubber-like state. While in the more brittle state, the polymer matrix prevents free rotation of the photochromic chromophore, locking the photochromic chromophore into a colorless or a light-absorbing state. However, when in the less brittle, more molten state, the polymer matrix allows free rotation of the photochromic chromophore between colorless or light-absorbing states. Consequently, in this embodiment, a mask can be configured to switch between a state with one degree of opacity to a state with another degree of opacity, through the simple application of heat and activating light.



FIG. 7 is a flowchart illustrating an embodiment of a method for controlling the opacity of a photochromic polymer mask configured to switch between different levels of opacity. At step 4000, a switchable mask implanted in the eye is exposed to both heat and an activating light source. The exposure to heat causes the polymer matrix to undergo a glass transition while the light activation of the photochromic chromophores causes the molecules to rotate and absorb visible light, causing the transition portion on the mask to become more opaque 4002. In step 4004, the heat source is removed and the polymer matrix undergoes a glass transition back to a more brittle form, thus locking in the light-absorbing photochromic chromophores so that they can no longer rotate, resulting in retention of the enhanced opacity of the transition portion. In step 4006, the activating light source is removed; however the mask remains opaque because the energy-activated photochromic chromophores are not able to freely rotate back into a relaxed colorless state. In optional step 4008, heat is again applied to the mask, causing the polymer matrix to again undergo a glass transition. This glass transition allows the photochromic chromophores to freely rotate back into their relaxed, colorless state, causing the mask to become less opaque. In optional step 4010, the heat source is removed from the mask and the polymer matrix undergoes a glass transition back to a more brittle state, locking the photochromic chromophores into a non-rotatable state. Thus, in this example, the mask has been switched from a state with one degree of opacity to a state with another degree of opacity and back again, by the application of heat and activating light.


In some embodiments, a mask configured to controllably switch between different levels of opacity is advantageous because it can allow treatment providers to inspect the back of the eye without requiring the removal of the mask. Further, in certain embodiments, such a feature can allow for switchable changes in mask geometry from outside the eye, potentially allowing for the adjustment of the masks from a first opacity to a second different opacity for various treatments or performance objectives.


In some embodiments, the transition portion of the mask can comprise any proportion of the total mask, ranging from above 0% to 100% of the mask. For example, the transition portion can be at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, or about 100% of the total area of the opaque portion of the mask.


In certain embodiments, the transition portion can switch between a first level of opacity that blocks the transmittance of substantially all light and a second level of opacity where substantially all light can pass through the mask. In some embodiments, the mask can be configured to switch between any level of opacity ranging from above 0 to 100%, corresponding to blocking between 0% to 100% of visible light, respectively. For example, the change in the level of opacity between the first level and the second level can be at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or more.



FIGS. 8A-8F depict embodiments of various geometric configurations for the transition portion of the mask. For example, the switchable portion of the mask can switch between a uniform high transmission 5000 (FIG. 8A) and another degree of opacity via switching of a portion of the mask such as in the top half 5002 (FIG. 8B) or an inner annulus 5004 (FIG. 8C), or the entire mask such as in 5006 (FIG. 8D) and 5008 (FIG. 8E). In further embodiments, multiple transition portions are configured to switch between various levels of opacity 5010 (FIG. 8F).


For example, referring to FIG. 8F, a mask 5010 having a central aperture 5012 is illustrated. A first annular zone 5014 surrounds the aperture 5012. A second annular zone 5016 surrounds the first annular zone 5014. A third annular zone (not illustrated) may surround the second annular zone 5016. Each of the annular zones may comprise a homogeneous optical transmission characteristic, or may comprise an annular ring of two or more alternating or intermittent sections having distinct absorption characteristics.


In one implementation of the invention, the outer annular ring 5016 comprises a fixed opacity. The inner ring 5014 comprises a transition portion as described elsewhere herein. The opacity of the transition portion may be adjusted between a first opacity that is relatively high, such as substantially equivalent to the opacity of the outer zone 5016, and a reduced opacity as described elsewhere herein. In effect, the invention enables the provision of a mask 5010 having an aperture 5012 of a first diameter. Adjustment of the opacity of the inner ring 5014 from a relatively high opacity to a relatively low opacity has the effect of increasing the diameter of the central aperture 5012. This may be desirable for altering the optical characteristics of the mask, or for increasing the visual access to the interior of the eye for diagnostic or therapeutic purposes.


Alternatively, the relationship between the fixed ring and the variable ring may be reversed. Thus, the inner ring 5014 may be provided with a permanent opacity. The outer ring 5016 may be provided with a variable characteristic such that the opacity may be changed between a relatively low level and a relatively high level.


In general, the mask of the present invention may be provided on an intraocular lens, a corneal inlay, or elsewhere along the optical path. It may be provided with at least a first region having a predetermined transmission characteristic, and at least a second region having a controllable variable transmission characteristic.


The variable opacity characteristic can be accomplished by any of a variety of systems in which a change in opacity may be accomplished in response to exposure to an external stimulus. The external stimulus can be ultraviolet, visible or infrared light, heat, a radiofrequency or magnetic field, electrical current, mechanical vibration (e.g. ultrasound) or other triggering signal that can be applied to the eye. Certain chemical systems which respond to an exposure to light will be described further herein.


As described above, in some embodiments, the mask contains at least one transition portion with photochromic chromophores contained within a polymer matrix. In a preferred embodiment, the photochromic chromophore is spiropyran, although other photochromic chromophores can be used. For example, any photochromic chromophore that undergoes a stereochemical conformational change that can be locked within a polymer matrix can be used. In certain embodiments, the photochromic chromophore or other compound can be any suitable molecule or compound that can be bound into a polymer chain. Further suitable chromophores include, but are not limited to: naphthopyrans, chromenes, fulgides, similar molecules, and mixtures thereof. In other embodiments, dimers of the photochromic chromophore can be used such as, for example, a spiropyran dimer. Desirably, in embodiments, the photochromic chromophore or compound is one that can easily rearrange in the photochromic polymer to alter the transmission state when exposed to suitable irradiation and heat, but which is more difficult to rearrange in the photochromic polymer to alter the transmission state when heat is removed. For example, further details concerning the use of photochromic chromophores within a polymer matrix can be found in U.S. Pat. No. 8,216,765, entitled “REIMAGEABLE AND REUSABLE MEDIUM AND METHOD OF PRODUCING AND USING THE REIMAGEABLE AND REUSABLE MEDIUM,” filed Mar. 9, 2009. and which is hereby incorporated by reference in its entirety.


In certain embodiments, the photochromic chromophore concentration within the polymer matrix of the transition portion can be varied to result in a range of switchable opacities. For example, the concentration of photochromic chromophore can be varied to produce a switchable level of opacity within the transition portion having a change in transmission of at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least 50%, at least about 60%, at least about 70%, or more between the high transmission and low transmission states.


In some embodiments, the photochromic chromophore can be distributed homogenously throughout the transition portions of the mask, resulting in a constant level of opacity across the transition portions of the mask. In certain embodiments, the photochromic chromophore can be distributed heterogeneously throughout the transition portions of the mask, resulting in a non-constant level of opacity across the transition portions of the mask.


In some embodiments, the wavelength of light used to activate the photochromic chromophore to switch from a colorless or high transmission state to an opaque or relatively lower transmission state can be any wavelength of light capable of triggering an absorption transition. In certain embodiments, the wavelength of light used to activate the photochromic chromophore to switch from a colorless state to an opaque state is in the ultraviolet range. In further embodiments, the wavelength of light used to activate the photochromic chromophore is in the infrared range. In additional embodiments, the wavelength of light used to activate the photochromic chromophores is in the visible light range.


In certain embodiments, the photochromic chromophore contained within the transition portion of the mask can be selected so as to allow for exposure to selected events such as illumination and imaging via a camera without activating the photochromic chromophore. For example, the wavelength of light used by the camera to illuminate and image the mask can be of such a different wavelength of light from the activating wavelength of the photochromic chromophore that the light from the camera will not activate the photochromic chromophore. In some embodiments, near infrared light could be used by the camera, while ultraviolet light is used for the photochromic chromophore.


In certain embodiments, the wavelength of energy used by the illuminating and imaging camera is the same as the wavelength of energy used to heat the system. In some embodiments, the wavelength of energy used by the camera is different from the wavelength of energy used to heat the system.


As described above, in some embodiments, the transition portions of the mask contain light-activated photochromic chromophores contained within a polymer matrix with a controlled Tg. In some embodiments, the photochromic chromophore is polymerized directly into the backbone of the polymer used in the polymer matrix. Suitable photochromic chromophores are described above, however, in some embodiments suitable polymers can be formed from first and second monomers. For example, further details concerning the formation of first and second monomers and incorporation of a photochromic chromophore into a polymer matrix can be found in U.S. Pat. No. 8,216,765, entitled “REIMAGEABLE AND REUSABLE MEDIUM AND METHOD OF PRODUCING AND USING THE REIMAGEABLE AND REUSABLE MEDIUM,” filed Mar. 9, 2009 and which was incorporated by reference above. FIG. 9 illustrates one embodiment of a synthesis scheme for a photochromic monomer. FIG. 10 illustrates one embodiment of a synthesis scheme for the synthesis of a photochromic polymer from the co-polymerization of a photochromic monomer.


In certain embodiments, the photochromic polymer is optionally dissolved or dispersed in any suitable carrier, such as a solvent, a polymer binder, or the like. Water may be used as a solvent for water soluble photochromic polymers and water-soluble binders such as poly(vinyl alcohol) and poly(acrylic acid). Other suitable solvents include, for example, straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons, and the like, such as where the straight or branched chain aliphatic hydrocarbons have from about 1 to about 30 carbon atoms. For example, a non-polar liquid of the ISOPAR™ series (manufactured by the Exxon Corporation) may be used as the solvent. These hydrocarbon liquids are considered narrow portions of iso-paraffinic hydrocarbon fractions. Other suitable solvent materials include, for example, the NORPAR™ series of liquids, which are compositions of n-paraffins available from Exxon Corporation, the SOLTROL™ series of liquids available from the Phillips Petroleum Company, and the SHELLSOL™ series of liquids available from the Shell Oil Company. Mixtures of one or more solvents, i.e., a solvent system, can also be used, if desired. In addition, more polar solvents can also be used, if desired. Examples of more polar solvents that may be used include halogenated and nonhalogenated solvents, such as tetrahydrofuran, trichloro- and tetrachloroethane, dichloromethane, chloroform, monochlorobenzene, toluene, xylenes, acetone, methanol, ethanol, xylenes, benzene, ethyl acetate, dimethylformamide, cyclohexanone, N-methyl acetamide and the like. The solvent may be composed of one, two, three or more different solvents. When two or more different solvents are present, each solvent may be present in an equal or unequal amount by weight ranging for example from about 5% to 90%, particularly from about 30% to about 50%, based on the weight of all solvents.


In some embodiments, the photochromic polymer can be dispersed in another, non-photochromic polymer binder. Such an additional polymer binder may be desired, for example, depending on the properties, characteristics, and the like of the photochromic polymer. Of course, it will be understood that an additional polymer binder may not be required in some embodiments, as the photochromic polymer can itself function as a binder material. Suitable examples of polymer binders that can be used include, but are not limited to, polyalkylacrylates like polymethyl methacrylate (PMMA), polycarbonates, polyethylenes, oxidized polyethylene, polypropylene, polyisobutylene, polystyrenes, poly(styrene)-co-(ethylene), polysulfones, polyethersulfones, polyarylsulfones, polyarylethers, polyolefins, polyacrylates, polyvinyl derivatives, cellulose derivatives, polyurethanes, polyamides, polyimides, polyesters, silicone resins, epoxy resins, polyvinyl alcohol, polyacrylic acid, and the like. Copolymer materials such as polystyrene-acrylonitrile, polyethylene-acrylate, vinylidenechloride-vinylchloride, vinylacetate-vinylidene chloride, styrene-alkyd resins are also examples of suitable binder materials. The copolymers may be block, random, or alternating copolymers. In some embodiments, polymethyl methacrylate or a polystyrene is the polymer binder, in terms of their cost and wide availability. The polymer binder, when used, has the role to provide a coating or film forming composition.


Phase change materials can also be used as the polymer binder. Phase change materials are known in the art, and include for example crystalline polyethylenes such as Polywax® 2000, Polywax® 1000, Polywax® 500, and the like from Baker Petrolite, Inc.; oxidized wax such as X-2073 and Mekon wax, from Baker-Hughes Inc.; crystalline polyethylene copolymers such as ethylene/vinyl acetate copolymers, ethylene/vinyl alcohol copolymers, ethylene/acrylic acid copolymers, ethylene/methacrylic acid copolymers, ethylene/carbon monoxide copolymers, polyethylene-b-polyalkylene glycol wherein the alkylene portion can be ethylene, propylene, butylenes, pentylene or the like, and including the polyethylene-b-(polyethylene glycol)s and the like; crystalline polyamides; polyester amides; polyvinyl butyral; polyacrylonitrile; polyvinyl chloride; polyvinyl alcohol hydrolyzed; polyacetal; crystalline poly(ethylene glycol); poly(ethylene oxide); poly(ethylene therephthalate); poly(ethylene succinate); crystalline cellulose polymers; fatty alcohols; ethoxylated fatty alcohols; and the like, and mixtures thereof.


In some embodiments, any suitable polymer that has one or more photochromic molecules or compounds bound to the polymer backbone, can be used. Such photochromic polymers can have the photochromic molecules or compounds covalently bound to the polymer backbone within the polymer chain itself. Such groups can be introduced into the polymer chain, for example, by including the photochromic molecules or compounds during the polymer preparation process, such as in the form of reactive units, monomer units, or the like, or they can be added to an already formed non-photochromic polymer material through known chemical functionalization reactions.


Where multiple photochromic molecules or compounds are present in the polymer chain, the multiple photochromic molecules or compounds can be the same or different. Likewise, the photochromic polymer can include only one type of photochromic polymer, or can include a mixture of two or more different types of photochromic polymer (such as different photochromic polymers having different photochromic molecules or compounds in the polymer chain, or the same or different photochromic molecules or compounds in different polymer chains. Because the photochromic polymer is converted between its colored and colorless states by the use of light and heat, the polymer and photochromic molecules or compounds are desirably selected such that the photochromic polymer has thermal properties that can withstand the elevated temperatures that may be used.



FIG. 11 depicts an embodiment of a suitable incorporation of a photochromic chromophore into a polymer backbone. In this illustrative embodiment, the photochromic chromophore can be between a first and second monomer. Likewise, any suitable non-photochromic polymer materials may be selected for forming the non-photochromic parts of the photochromic polymer. Examples include, but are not limited to, the polymers described above as useful for a polymer binder. For example, in one embodiment, suitable polymers include those that can be formed from first and second monomers. The first monomer may be diacyl chlorides, diacids, its dimethyl esters, or its unhydrous cyclic esters such as oxalyl, malonyl, succinyl, glutaryl, adipoyl, pimeloyl, suberoyl, azelaoyl, sebacoyl, fumaryl, terephthalic, isophthalic, phthalic, and mixtures thereof, wherein the alkyl portion can be a straight, branched or cyclic, saturated or unsaturated, substituted or unsubstituted, from 1 to about 40 carbon atoms, a substituted or unsubstituted aromatic or heteroaromatic group. The second monomer may be bisphenols or diols such as Bis-phenol A, bisphenol B, bisphenol C, bisphenol F, bisphenol M, bisphenol P, bisphenol AP, bisphenol Z, ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, heptylene glycoldiethylene glycol, dipropylene glycol, dipropylene glycol, cyclohexyldimethanol, bisphenol A ethoxylate, bisphenol A propoxylate, and mixtures thereof, wherein the alkyl portion can be a straight, branched or cyclic, saturated or unsaturated, substituted or unsubstituted, from 1 to about 40 carbon atoms, an substituted or unsubstituted aromatic or heteroaromatic group.


In certain embodiments, a photochromic polymer containing a photochromic chromophore within a polymer backbone is mixed with a second miscible polymer with side-chain crystallizable side groups such as polyoctadecyl acrylate. For example, further details concerning side-chain crystallizable polymers can be found in U.S. Pat. No. 4,830,855, entitled “TEMPERATURE-CONTROLLED ACTIVE AGENT DISPENSER,” filed Nov. 13, 1987 and which is hereby incorporated by reference in its entirety. In certain embodiments, the photochromic chromophore can be polymerized directly into side-chain crystallizable polymers. In certain embodiments, the first and/or second monomers described above can be side-chain crystallizable polymers.



FIG. 12 depicts an embodiment of a side-chain crystallizable polymer, where X is a first monomer unit, Y is a second monomer unit, Z is a backbone atom, S is a spacer unit and C is a crystallizable group. Side-chain crystallizable polymers, sometimes called “comb-like” polymers are well known and available commercially. These polymers are reviewed in J. Poly. Sci.: Macromol. Rev. (1974) 8: 117-253. In some embodiments the molecular weight of C is equal to or greater than twice the sum of the molecular weights of X, Y and Z. These polymers have a heat of fusion (—Ht) of at least about 5 calories/g, preferably at least about 10 calories/g. The backbone of the polymer (defined by X, Y and Z) may be any organic structure (aliphatic or aromatic hydrocarbon, ester, ether, amide, etc.) or an inorganic structure (sulfide, phosphazine, silicone, etc.). The spacer linkages can be any suitable organic or inorganic unit, for example ester, amide, hydrocarbon, phenyl, ether, or ionic salt (for example a carboxyl-alkyl ammonium or sulphonium or phosphonium ion pair or other known ionic salt pair). The side-chain (defined by S and C) may be aliphatic or aromatic or a combination of aliphatic and aromatic, but must be capable of entering into a crystalline state. Common examples are linear aliphatic side-chains of at least 10 carbon atoms, fluorinated aliphatic side-chains of at least 6 carbons, and p-alkyl styrene side-chains wherein the alkyl is of 8 to 24 carbon atoms.


In some embodiments, the length of the side-chain moiety is usually greater than 5 times the distance between side-chains in the case of acrylates, methacrylates, vinyl esters, acrylamides, methacrylamides, vinyl ethers and alpha olefins. In certain embodiments, a fluoroacrylate alternate copolymer with butadiene as the side-chain can be as little as 2 times the length as the distance between branches. In some embodiments, the side-chain units should make up greater than 50% of the volume of the polymer, preferably greater than 65% of the volume. Co-monomers added to a side-chain polymer usually have an adverse effect on crystallinity. Small amounts of various co-monomers can be tolerated, usually up to 10 to 25 volume percent. In some embodiments, it is desirable to add small amounts of co-monomer, for example cure site monomers such as acrylic acid, glycidal methacrylate, maleic anhydride, amino function monomer and the like. Specific examples of side-chain crystallizable monomers are the acrylate, fluoroacrylate, methacrylate and vinyl ester polymers described in J. Poly. Sci. (1972) 10:50 3347; J. Poly. Sci. (1972) 10: 1657; J. Poly. Sci. (1971) 9:3367; J. Poly. Sci. (1971) 9: 3349; J. Poly. Sci. (1971) 9:1835; J.A.C.S. (1954) 76: 6280; J. Poly. Sci. (1969) 7: 3053; Polymer J. (1985) 17: 991. corresponding acrylamides, substituted acrylamide and maleimide polymers (J. Poly. Sci., Poly. Physics Ed. (1980) 18: 2197; polyalphaolefin polymers such as those described in J. Poly. Sci.: Macromol. Rev. (1974) 8: 117-253 and Macromolecules (1980) 13: 12, polyalkylvinylethers, polyalkylethylene oxides such as those described in Macromolecules (1980) 13: 15, alkylphosphazene polymers, polyamino acids such as those described in Poly. Sci. USSR (1979) 21: 241, Macromolecules (1985) 18: 2141, polyisocyanates such as those described in Macromolecules (1979) 12: 94. polyurethanes made by reacting amine- or alcohol-containing monomers with long chain alkyl isocyanates, polyesters and poly ethers. Polysiloxanes and polysilanes such as those described in Macromolecules (1986) 19: 611 and p-alkylstyrene polymers such as those described in J.A.C.S. (1953) 75: 3326 and J. Poly. Sci. (1962) 60: 19.


In certain embodiments, the photochromic chromophore can be incorporated into a polyester polycondensate. For example, further details concerning this type of incorporation can be found in U.S. Pat. No. 3,918,972, entitled “IMAGING PROCESS UTILIZING A POLYESTER POLYCONDENSATE CONTAINING SPIROPYRAN PHOTOCHROMIC GROUPS” filed Aug. 13, 1973 and hereby incorporated by reference in its entirety. Further details concerning additional photochromic polycondensates can be found in U.S. Pat. No. 4,026,869 entitled PHOTOCHROMIC POLYCONDENSATES, filed Jul. 21, 1975 and hereby incorporated by reference in its entirety.


In some embodiments, linear polycondensates of the polyester type are provided characterized in that they contain spiropyran photochromic groups as an integral part of the main polymer chain. In certain embodiments, they can be prepared by polycondensation of Bisphenol-A and a photochromic compound carrying a hydroxyalkyl group on either side of the photochromic moiety, with a dicarboxylic acid of the saturated dicarboxylic acid series, preferably with succinic acid, adipic acid, glutaric acid and pimelic acid. In this process the dicarboxylic acid in the form of a diacid dichloride is dissolved in an organic liquid, such as methylene chloride, dichloroethane, tetrachloroethane, benzene or toluene, which is also a solvent for the copolycondensate to be formed. The bisphenol is dissolved in another liquid, which is immiscible with the above organic liquid. Preferably water is used as a solvent for the bisphenol and an equivalent amount of a metal hydroxide, such as sodium hydroxide or potassium hydroxide is added to the water in order to form immediately the corresponding diphenolate. The reaction speed is greatly increased by using quaternary ammonium compounds as catalysts. The two solutions are mixed and stirred vigorously at the reaction temperature, whereby the copolyester is formed in solution. In the same way the photochromic copoly-condensates of the invention are formed. In some embodiments, a photochromic compound carrying on either side of the photochromic moiety an hydroxyalkylgroup is made to react with an excess of the diacid dichloride e.g. of succinic acid, adipic acid, glutaric acid, or pimelic acid, and the photochrome-bis-acid chloride formed in this way is made to react in a two-phase reaction mixture with a diphenolate of bisphenol-A. Suitable photochromic compounds carrying two hydroxyalkyl groups on either side of the photochromic moiety are compounds, containing spiropyran groups.


In certain embodiments, the photochromic chromophore is directly polymerized into a polymer backbone as described above and mixed with the miscible polymer combination described above. In some embodiments, the photochromic dye is directly polymerized into the polymer backbone of a polymer that also has side chain crystallizable side groups such as described above. In certain embodiments, the photochromic oligomers or monomers described above and in U.S. Pat. No. 8,216,765 can be mixed with the aforementioned miscible combination of polymers. In some embodiments, a dimer of any of the aforementioned photochromic chromophores can be mixed with any of the aforementioned polymers.


In further embodiments, the Tg of the polymer matrix can be between 30°-150° C. For example, the Tg can be at least about 30° C., about 35° C., about 40° C., about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., about 70° C., about 75° C., about 80° C., about 85° C., about 90° C., about 95° C., about 100° C., about 105° C., about 110° C., about 115° C., about 120° C., about 125° C., about 130° C., about 135° C., about 140° C., about 145° C., or about 150° C.


The Tg of the polymer matrix can be varied by changing the chemical properties of the polymers comprising the polymer matrix. In some embodiments, the Tg of the polymer matrix can be modified by varying the chain length of the monomer used in polymerization. In further embodiments, the Tg is controlled by varying the chain length of the side groups that branch from the polymer backbone. In other embodiments, the Tg of the polymer matrix can be adjusted by varying the spacing between the side-chains. In certain embodiments, the Tg of the polymer is controlled by varying the cross-link density of the polymer. In other embodiments, the Tg of the polymer can be controlled by varying the molecular weight of the polymer. Any of the aforementioned polymer properties can be adjusted together or separately to tune the Tg of the polymer matrix.


As described previously, in some embodiments, heat can be used to cause the polymer matrix to undergo a glass transition. In certain embodiments, heat is provided to the polymer matrix via focused radiant energy from outside the eye. For example, this focused radiant energy can be a laser. In some embodiments, ultrasonic energy can be applied to the mask to heat it. In some embodiments, heat or other initiator is applied to the transition portions, or to one of multiple transition portions of the mask.


In some embodiments, an axicon lens can be used to focus a circular beam of radiant energy into the eye and onto a mask to heat an annular area of the mask inside the eye. In certain embodiments, the annular pattern created by the axicon lens can be focused further before entering the eye to create a confocal focusing of the annular pattern to bring it to a smaller, higher energy density annular region of focus inside the eye on the mask. In certain embodiments, a biconvex toric lens could be used to achieve the confocal focusing of the annular pattern output from the axicon lens element to focus it confocally into the eye. In some embodiments, other optical configurations instead of an axicon lens can be used to provide a confocally focused annular beam of energy into the eye.


In some embodiments, focusing of the radiant energy into the eye and onto the mask would be completed with simultaneous microscope viewing for better control and monitoring of the procedure inside the eye. This arrangement is advantageous, as the focus of the radiation area on the mask and the change of the photochromic chromophores in this area could be directly observed.


While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the device or process illustrated can be made without departing from the spirit of the disclosure. As will be recognized, certain embodiments of the inventions described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of the inventions is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims
  • 1. An ophthalmic device comprising: a mask configured to transmit substantially all visible light along an optical axis of the eye;the mask further comprising a transition portion configured to switch between a first degree of opacity and a second degree of opacity in response to application of an external stimuli;wherein the transition portion is configured to remain locked into the second degree of opacity after removal of the external stimuli until another application of the external stimuli, the transition portion then returning to the first degree of opacity; andwherein the transition portion comprises a photochromic chromophore within a polymer matrix.
  • 2. The ophthalmic device of claim 1, wherein the mask further comprises an aperture configured to transmit substantially all visible light along the optical axis of the eye.
  • 3. The ophthalmic device of claim 1, wherein the mask further comprises a plurality of holes extending at least partially between an anterior surface of the mask and a posterior surface of the mask.
  • 4. The ophthalmic device of claim 1, further comprising an intraocular lens coupled with the mask.
  • 5. The ophthalmic device of claim 1, wherein the second degree of opacity allows transmission of substantially all visible light through the transition portion of the mask.
  • 6. The ophthalmic device of claim 1, wherein the first degree of opacity prevents transmission of substantially all visible light through the transition portion of the mask.
  • 7. The ophthalmic device of claim 1, wherein the transition portion of the mask comprises at least 50% of the total mask.
  • 8. The ophthalmic device of claim 1, wherein the photochromic chromophore is spiropyran.
  • 9. The ophthalmic device of claim 1, wherein the transition portion is configured to switch between a first degree of opacity and a second degree of opacity via application of both light and heat.
  • 10. The ophthalmic device of claim 1, wherein the polymer matrix has a glass transition temperature of between 30-150° C.
  • 11. The ophthalmic device of claim 1, wherein the external stimuli is chosen from the group consisting of light, heat, and electrical current.
  • 12. The ophthalmic device of claim 1, wherein the external stimuli comprises heat provided by a laser.
  • 13. The ophthalmic device of claim 1, wherein the external stimuli comprises a combination of light and heat.
  • 14. The ophthalmic device of claim 1, wherein the glass transition temperature of the polymer matrix is approximately 50° C.
  • 15. The ophthalmic device of claim 1, wherein the polymer matrix comprises a side-chain crystallizable polymer.
  • 16. The ophthalmic device of claim 1, wherein the mask is configured to switch between the first degree of opacity, the second degree of opacity, and a third degree of opacity in response to an external stimuli.
  • 17. The ophthalmic device of claim 1, wherein the transition portion is further configured to remain locked into the first degree of opacity until application of the external stimuli.
  • 18. The ophthalmic device of claim 1, wherein the polymer matrix comprises polymethyl methacrylate.
  • 19. An intraocular mask, comprising: a photochromic chromophore within a polymer matrix, the photochromic chromophore configured to rotate between a first state wherein the intraocular mask comprises a first degree of opacity and a second state wherein the intraocular mask comprises a second degree of opacity, the photochromic chromophore configured to rotate only when the polymer matrix has passed through a glass transition from a brittle state into a molten state in response to application of an external stimuli, the polymer matrix configured to return to the brittle state upon removal of the external stimuli and remain locked in the brittle state until another application of the external stimuli.
  • 20. The intraocular mask of claim 19, wherein the photochromic chromophore is substantially opaque while in the first state.
  • 21. The intraocular mask of claim 20, wherein the photochromic chromophore is substantially colorless while in the second state.
US Referenced Citations (723)
Number Name Date Kind
564518 Heilborn Jul 1896 A
1034516 Samberg Aug 1912 A
1206132 Otte Nov 1916 A
1959915 Guthrie May 1934 A
2129305 Feinbloom Sep 1938 A
2350421 Schoder et al. Jun 1944 A
2470927 Hale, Jr. May 1949 A
2714721 Stone, Jr. Aug 1955 A
3034403 Neefe May 1962 A
3074407 Moon et al. Jan 1963 A
3270099 Camp Aug 1966 A
3339997 Wesley Sep 1967 A
3392727 Hanlon Jul 1968 A
D212868 Olson Dec 1968 S
3458870 Stone, Jr. Aug 1969 A
3507566 Knapp Apr 1970 A
3536386 Spivack Oct 1970 A
3578850 Grant May 1971 A
3600098 Mohrman Aug 1971 A
3726587 Kendall Apr 1973 A
3776230 Neefe Dec 1973 A
3794414 Wesley Feb 1974 A
3852032 Urbach Dec 1974 A
3877502 Hunckler Apr 1975 A
3914013 Rosenberg Oct 1975 A
3918972 Evens et al. Nov 1975 A
3946982 Calkins et al. Mar 1976 A
3982541 L'Esperance, Jr. Sep 1976 A
4010496 Neefe Mar 1977 A
4026869 Evens et al. May 1977 A
4073015 Peyman Feb 1978 A
4099529 Peyman Jul 1978 A
4116439 Chavarria et al. Sep 1978 A
4138191 Peyman Feb 1979 A
4191195 Miller Mar 1980 A
4210391 Cohen Jul 1980 A
4272191 Bergkvist Jun 1981 A
4298004 Schachar et al. Nov 1981 A
4312575 Peyman et al. Jan 1982 A
4340283 Cohen Jul 1982 A
4367949 Lavering Jan 1983 A
4383843 Iyenger May 1983 A
4402579 Poler Sep 1983 A
4402681 Haas et al. Sep 1983 A
4409979 Roussel et al. Oct 1983 A
4423728 Lieberman Jan 1984 A
4445892 Hussein et al. May 1984 A
4450593 Poler May 1984 A
4452235 Reynolds Jun 1984 A
4461294 Baron Jul 1984 A
4469098 Daui Sep 1984 A
4485499 Castleman Dec 1984 A
4505855 Bruns et al. Mar 1985 A
4528311 Beard et al. Jul 1985 A
4536240 Winn Aug 1985 A
4538608 L'Esperance, Jr. Sep 1985 A
4547914 Castleman Oct 1985 A
4547915 Castleman Oct 1985 A
4563565 Kampfer et al. Jan 1986 A
4573998 Mazzocco Mar 1986 A
4575373 Johnson Mar 1986 A
4575915 Clark et al. Mar 1986 A
4576453 Borowsky Mar 1986 A
4582402 Knapp Apr 1986 A
4607617 Choyce Aug 1986 A
4612012 White Sep 1986 A
4615702 Koziol et al. Oct 1986 A
4617023 Peyman Oct 1986 A
4624669 Grendahl Nov 1986 A
4633866 Peyman et al. Jan 1987 A
4636049 Blaker Jan 1987 A
4636211 Nielsen et al. Jan 1987 A
4636212 Posin et al. Jan 1987 A
4637697 Freeman Jan 1987 A
4639105 Neefe Jan 1987 A
4641934 Freeman Feb 1987 A
4642112 Freeman Feb 1987 A
4646720 Peyman Mar 1987 A
4648400 Schneider et al. Mar 1987 A
4655774 Choyce Apr 1987 A
4662370 Hoffmann et al. May 1987 A
4665913 L'Esperance, Jr. May 1987 A
4666249 Bauman et al. May 1987 A
4666446 Koziol et al. May 1987 A
4669466 L'Esperance, Jr. Jun 1987 A
4669834 Richter Jun 1987 A
4672021 Blumel et al. Jun 1987 A
4674503 Peyman et al. Jun 1987 A
4676790 Kern Jun 1987 A
4676791 Le Master et al. Jun 1987 A
4678422 York Jul 1987 A
4685921 Peyman Aug 1987 A
4685922 Peyman Aug 1987 A
4701038 Neefe Oct 1987 A
4702574 Bawa Oct 1987 A
4702865 Koziol et al. Oct 1987 A
4704016 de Carle Nov 1987 A
4710003 Masuda et al. Dec 1987 A
4713446 DeVore et al. Dec 1987 A
4715858 Lindstrom Dec 1987 A
4718418 L'Esperance, Jr. Jan 1988 A
4729372 L'Esperance, Jr. Mar 1988 A
4729373 Peyman Mar 1988 A
4732148 L'Esperance, Jr. Mar 1988 A
4744360 Bath May 1988 A
4753654 Posin et al. Jun 1988 A
4767647 Bree Aug 1988 A
4779973 Miller et al. Oct 1988 A
4785796 Mattson Nov 1988 A
4785810 Baccala et al. Nov 1988 A
4787903 Grendahl Nov 1988 A
4795462 Grendahl Jan 1989 A
4796623 Krasner et al. Jan 1989 A
4798608 Grendahl Jan 1989 A
4799478 Fedorov et al. Jan 1989 A
4799784 Safir Jan 1989 A
4799931 Lindstrom Jan 1989 A
4806382 Goldberg et al. Feb 1989 A
4807623 Lieberman Feb 1989 A
4808181 Kelman Feb 1989 A
4813955 Achatz et al. Mar 1989 A
4814050 McGraw et al. Mar 1989 A
4817789 Paul Apr 1989 A
4830855 Stewart May 1989 A
4838266 Koziol et al. Jun 1989 A
4840175 Peyman Jun 1989 A
4842599 Bronstein Jun 1989 A
4849323 Endo et al. Jul 1989 A
4851003 Lindstrom Jul 1989 A
4863466 Schlegel Sep 1989 A
4865601 Caldwell et al. Sep 1989 A
4869587 Breger Sep 1989 A
4878910 Koziol et al. Nov 1989 A
4881860 Kanazawa Nov 1989 A
4881954 Bikson et al. Nov 1989 A
4889795 Kaifu et al. Dec 1989 A
4890913 De Carle Jan 1990 A
4891043 Zeimer et al. Jan 1990 A
4892543 Turley Jan 1990 A
4898461 Portney Feb 1990 A
4903695 Warner et al. Feb 1990 A
4907586 Bille et al. Mar 1990 A
4923297 Arndt May 1990 A
4928815 Paul May 1990 A
4932970 Portney Jun 1990 A
4955904 Atebara et al. Sep 1990 A
4958922 Binh et al. Sep 1990 A
4959070 McDonald Sep 1990 A
4961744 Kilmer et al. Oct 1990 A
4965545 Johnson Oct 1990 A
4971432 Koeniger Nov 1990 A
4976709 Sand Dec 1990 A
4976732 Vorosmarthy Dec 1990 A
4983181 Civerchia Jan 1991 A
4985559 Goldberg et al. Jan 1991 A
4990165 Bikson et al. Feb 1991 A
4994058 Raven et al. Feb 1991 A
4994080 Shepard Feb 1991 A
4997268 Dauvergne Mar 1991 A
5002571 O'Donnel, Jr. Mar 1991 A
5013319 Davis May 1991 A
5019097 Knight et al. May 1991 A
5026393 Mackool Jun 1991 A
D318117 Michelson Jul 1991 S
5030230 White Jul 1991 A
5041133 Sayano et al. Aug 1991 A
5055602 Melpolder Oct 1991 A
5061914 Busch et al. Oct 1991 A
5063942 Kilmer et al. Nov 1991 A
5065516 Dulebohn Nov 1991 A
5067961 Kelman et al. Nov 1991 A
5076684 Simpson et al. Dec 1991 A
D323891 Arkel Feb 1992 S
5087015 Galley Feb 1992 A
5089022 Koester et al. Feb 1992 A
5089024 Christie et al. Feb 1992 A
5090955 Simon Feb 1992 A
5092874 Rogers Mar 1992 A
5094521 Jolson et al. Mar 1992 A
5098443 Parel et al. Mar 1992 A
5098444 Feaster Mar 1992 A
D325500 Dennis Apr 1992 S
5104957 Kelman et al. Apr 1992 A
5108169 Mandell Apr 1992 A
5108427 Majercik et al. Apr 1992 A
5108428 Capecchi et al. Apr 1992 A
5112328 Taboada et al. May 1992 A
5112350 Civerchia et al. May 1992 A
5116111 Simpson et al. May 1992 A
5119555 Johnson Jun 1992 A
5120120 Cohen Jun 1992 A
5120121 Rawlings et al. Jun 1992 A
5123921 Werblin et al. Jun 1992 A
5133745 Falcetta et al. Jul 1992 A
5139518 White Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5151098 Loertascher Sep 1992 A
5152789 Willis Oct 1992 A
5156622 Thompson Oct 1992 A
5158572 Nielsen Oct 1992 A
5160463 Evans et al. Nov 1992 A
5165897 Johnson Nov 1992 A
5166712 Portney Nov 1992 A
5171318 Gibson et al. Dec 1992 A
5172143 Baude et al. Dec 1992 A
5185152 Peyman Feb 1993 A
5188125 Kilmer et al. Feb 1993 A
5188494 Hatin Feb 1993 A
5192316 Ting Mar 1993 A
5192318 Schneider et al. Mar 1993 A
5196026 Barrett et al. Mar 1993 A
5196027 Thompson et al. Mar 1993 A
5201762 Hauber Apr 1993 A
5203865 Siepser Apr 1993 A
5215104 Steinert Jun 1993 A
5219844 Peyman et al. Jun 1993 A
5225858 Portney Jul 1993 A
5239066 Falkow et al. Aug 1993 A
5245367 Miller et al. Sep 1993 A
5245738 Johnson Sep 1993 A
5258412 Peyman et al. Nov 1993 A
5260727 Oksman et al. Nov 1993 A
5261997 Inselmann Nov 1993 A
5269795 Arnott Dec 1993 A
5269812 White Dec 1993 A
5270744 Portney Dec 1993 A
5274404 Michael Dec 1993 A
5282971 Degen et al. Feb 1994 A
5288293 O'Donnell, Jr. Feb 1994 A
5288436 Liu et al. Feb 1994 A
5290301 Lieberman Mar 1994 A
5292514 Capecchi et al. Mar 1994 A
5296305 Baude et al. Mar 1994 A
5296881 Freeman Mar 1994 A
D345796 Pernicka Apr 1994 S
5300116 Chirila et al. Apr 1994 A
5300118 Silvestrini et al. Apr 1994 A
5302978 Evans et al. Apr 1994 A
5306297 Rheinish et al. Apr 1994 A
5310654 Isberg et al. May 1994 A
5312330 Klopotek May 1994 A
5312393 Mastel May 1994 A
5312424 Kilmer et al. May 1994 A
5314439 Sugita May 1994 A
5314961 Anton et al. May 1994 A
5315344 Clark et al. May 1994 A
5318044 Kilmer et al. Jun 1994 A
5318046 Rozakis Jun 1994 A
5318047 Davenport et al. Jun 1994 A
5322649 Rheinish et al. Jun 1994 A
5323788 Silvestrini et al. Jun 1994 A
5325880 Johnson et al. Jul 1994 A
5332802 Kelman et al. Jul 1994 A
5336261 Barrett et al. Aug 1994 A
5346689 Peyman et al. Sep 1994 A
5354331 Schachar Oct 1994 A
5358520 Patel Oct 1994 A
5366499 Py Nov 1994 A
5368604 Kilmer et al. Nov 1994 A
5372580 Simon et al. Dec 1994 A
5374272 Arpa et al. Dec 1994 A
D354566 Donahoo Jan 1995 S
5391201 Barret et al. Feb 1995 A
5401508 Manesis Mar 1995 A
5403335 Loomas et al. Apr 1995 A
5405384 Silvestrini Apr 1995 A
5414477 Jahnke May 1995 A
5422424 Selsted et al. Jun 1995 A
5433745 Graham et al. Jul 1995 A
5434630 Bransome Jul 1995 A
5437274 Khoobehi et al. Aug 1995 A
5441511 Hanna Aug 1995 A
5458819 Chirila et al. Oct 1995 A
5466260 Silvestrini et al. Nov 1995 A
5474548 Knopp et al. Dec 1995 A
5475452 Kuhn et al. Dec 1995 A
5476515 Kelman et al. Dec 1995 A
5480427 Kelman et al. Jan 1996 A
5489300 Capecchi et al. Feb 1996 A
5496339 Koepnick Mar 1996 A
5505722 Kilmer et al. Apr 1996 A
5505723 Muller Apr 1996 A
5507740 O'Donnel, Jr. Apr 1996 A
5507741 L'Esperance, Jr. Apr 1996 A
5507759 Nordan Apr 1996 A
5509922 Aranyi et al. Apr 1996 A
5516467 Niwa et al. May 1996 A
5516522 Peyman et al. May 1996 A
5522888 Civerchia Jun 1996 A
5526178 Goldstein et al. Jun 1996 A
5527356 Peyman et al. Jun 1996 A
5527524 Tomalia et al. Jun 1996 A
5547468 Simon et al. Aug 1996 A
5547473 Peyman Aug 1996 A
5567365 Weinschenk, III et al. Oct 1996 A
D375245 Irving Nov 1996 S
5571177 Deacon et al. Nov 1996 A
5579063 Magnante et al. Nov 1996 A
RE35421 Ruiz et al. Jan 1997 E
5591185 Kilmer et al. Jan 1997 A
5592246 Kuhn et al. Jan 1997 A
5599341 Mathis et al. Feb 1997 A
5599537 Miller, III et al. Feb 1997 A
5605938 Roufa et al. Feb 1997 A
5607437 Simon et al. Mar 1997 A
5607472 Thompson Mar 1997 A
5608471 Miller Mar 1997 A
5610719 Allen et al. Mar 1997 A
5624456 Hellenkamp Apr 1997 A
5627613 Kaneko May 1997 A
5628794 Lindstrom May 1997 A
5628795 Langerman May 1997 A
5628798 Eggleston et al. May 1997 A
5631243 Kelman et al. May 1997 A
5632773 Graham et al. May 1997 A
5643249 Amano Jul 1997 A
5645582 Silvestrini et al. Jul 1997 A
5647865 Swinger Jul 1997 A
5653752 Silvestrini et al. Aug 1997 A
5662706 Legerton et al. Sep 1997 A
5662908 Falkow et al. Sep 1997 A
5672885 Allen et al. Sep 1997 A
5674724 Miller, III et al. Oct 1997 A
5674736 Miller, III et al. Oct 1997 A
5693092 Silvestrini et al. Dec 1997 A
5695983 Miller et al. Dec 1997 A
5697923 Poler Dec 1997 A
5697973 Peyman et al. Dec 1997 A
5702440 Portney Dec 1997 A
5708049 Katagiri et al. Jan 1998 A
5713844 Peyman Feb 1998 A
5713957 Steele et al. Feb 1998 A
5719656 Bowling Feb 1998 A
5720894 Neev et al. Feb 1998 A
5722971 Peyman Mar 1998 A
5725575 O'Donnell, Jr. Mar 1998 A
5731196 Miller, III et al. Mar 1998 A
5731862 Winkler Mar 1998 A
5733334 Lee Mar 1998 A
5733760 Lu et al. Mar 1998 A
5746558 Nygren, Jr. et al. May 1998 A
5752960 Nallakrishnan May 1998 A
5752967 Kritzinger et al. May 1998 A
5757458 Miller et al. May 1998 A
5766171 Silvestrini Jun 1998 A
5769889 Kelman Jun 1998 A
5771088 Perrott Jun 1998 A
5771742 Bokaie et al. Jun 1998 A
5774202 Abraham et al. Jun 1998 A
5782911 Herrick Jul 1998 A
5785651 Kuhn et al. Jul 1998 A
5786883 Miller et al. Jul 1998 A
5800533 Eggleston et al. Sep 1998 A
5806530 Herrick Sep 1998 A
5814680 Imafuku et al. Sep 1998 A
5824086 Silvestrini Oct 1998 A
5833701 Gordon Nov 1998 A
5836313 Perez et al. Nov 1998 A
5840848 Sturrock et al. Nov 1998 A
5843105 Mathis et al. Dec 1998 A
5846186 Upsher Dec 1998 A
5846256 Mathis et al. Dec 1998 A
5855605 Herrick Jan 1999 A
5858980 Weiner et al. Jan 1999 A
5861486 Devore et al. Jan 1999 A
5863537 Dalliet et al. Jan 1999 A
5864128 Plesko Jan 1999 A
5864378 Portney Jan 1999 A
5865729 Meehan et al. Feb 1999 A
5870167 Knopp et al. Feb 1999 A
5874537 Kelman et al. Feb 1999 A
5876442 Lipshitz et al. Mar 1999 A
5888243 Silverstrini Mar 1999 A
5903099 Johnson et al. May 1999 A
5905561 Lee et al. May 1999 A
5919185 Peyman Jul 1999 A
5928283 Gross et al. Jul 1999 A
5929968 Cotie et al. Jul 1999 A
5935140 Buratto Aug 1999 A
5944752 Silvestrini Aug 1999 A
5960812 Johnson Oct 1999 A
5964748 Peyman Oct 1999 A
5964776 Peyman Oct 1999 A
5965330 Evans et al. Oct 1999 A
5968062 Thomas et al. Oct 1999 A
5980040 Xu et al. Nov 1999 A
5997559 Ziemer Dec 1999 A
6001386 Ashton et al. Dec 1999 A
6010510 Brown et al. Jan 2000 A
6010901 Miller, III et al. Jan 2000 A
6017121 Chateau et al. Jan 2000 A
6024447 Portney Feb 2000 A
6036957 Weiner et al. Mar 2000 A
D423669 Huttner Apr 2000 S
6050999 Paraschac et al. Apr 2000 A
6051023 Kilmer et al. Apr 2000 A
6063073 Peyman May 2000 A
6066171 Lipshitz et al. May 2000 A
6083236 Feingold Jul 2000 A
6086204 Magnante Jul 2000 A
6090141 Lindstrom Jul 2000 A
6096077 Callahan et al. Aug 2000 A
6102946 Nigam Aug 2000 A
6106552 Lacombe et al. Aug 2000 A
6110166 Juhasz Aug 2000 A
6125294 Scholl et al. Sep 2000 A
6126286 Portney Oct 2000 A
6138307 McDonald Oct 2000 A
6143010 Silvestrini Nov 2000 A
6152959 Portney Nov 2000 A
6161544 DeVore et al. Dec 2000 A
6164282 Gwon et al. Dec 2000 A
6165189 Ziemer Dec 2000 A
6171336 Sawusch Jan 2001 B1
6175754 Scholl et al. Jan 2001 B1
6176878 Gwon et al. Jan 2001 B1
6178593 Carlson Jan 2001 B1
6183498 DeVore et al. Feb 2001 B1
D439338 Huttner Mar 2001 S
6197019 Peyman Mar 2001 B1
6197057 Peyman et al. Mar 2001 B1
6197934 DeVore et al. Mar 2001 B1
6203538 Peyman Mar 2001 B1
6204365 DeVore et al. Mar 2001 B1
6210005 Portney Apr 2001 B1
6210401 Lai Apr 2001 B1
6214044 Silvestrini Apr 2001 B1
6217571 Peyman Apr 2001 B1
6217596 Farah Apr 2001 B1
6218360 Cintron et al. Apr 2001 B1
6221067 Peyman Apr 2001 B1
6221105 Portney Apr 2001 B1
6228113 Kauffman May 2001 B1
6228114 Lee May 2001 B1
6228115 Hoffmann et al. May 2001 B1
6231582 Gandianco et al. May 2001 B1
6251118 Proudfoot et al. Jun 2001 B1
6264648 Peyman Jul 2001 B1
D447237 Huttner et al. Aug 2001 S
6277146 Peyman et al. Aug 2001 B1
6280449 Blake Aug 2001 B1
6280470 Peyman Aug 2001 B1
6280471 Peyman Aug 2001 B1
6283595 Breger Sep 2001 B1
6302877 Ruiz Oct 2001 B1
6308590 Berto Oct 2001 B1
6312424 Largent Nov 2001 B1
6316153 Goodman et al. Nov 2001 B1
6335006 Miller Jan 2002 B1
6357875 Herrick Mar 2002 B1
6358280 Herrick Mar 2002 B1
6361560 Nigam Mar 2002 B1
6371973 Tepper Apr 2002 B1
6387379 Goldberg et al. May 2002 B1
6391055 Ikada et al. May 2002 B1
6399734 Hodd et al. Jun 2002 B1
6403947 Hoyt et al. Jun 2002 B1
6406494 Laguette et al. Jun 2002 B1
6413276 Werblin Jul 2002 B1
6416179 Lieberman et al. Jul 2002 B1
6419697 Kelman Jul 2002 B1
6423093 Hicks et al. Jul 2002 B1
6425917 Blake Jul 2002 B1
6432246 Blake Aug 2002 B1
6436092 Peyman Aug 2002 B1
6450642 Jethmalani et al. Sep 2002 B1
6454800 Dalton et al. Sep 2002 B2
6457826 Lett Oct 2002 B1
6458141 Peyman Oct 2002 B1
6470108 Johnson Oct 2002 B1
6488707 Callahan et al. Dec 2002 B1
6494910 Ganem et al. Dec 2002 B1
6497700 LaHaye Dec 2002 B1
6503276 Lang et al. Jan 2003 B2
6515006 Horn Feb 2003 B2
6520955 Reynard Feb 2003 B2
6527389 Portney Mar 2003 B2
6533905 Johnson et al. Mar 2003 B2
6536899 Fiala Mar 2003 B1
6551307 Peyman Apr 2003 B2
6554424 Miller et al. Apr 2003 B1
6554860 Hoffmann et al. Apr 2003 B2
6555103 Leukel et al. Apr 2003 B2
6569199 Dotan et al. May 2003 B1
6575573 Lai et al. Jun 2003 B2
6581993 Nigam Jun 2003 B2
RE38193 Bowling Jul 2003 E
6588022 Anders et al. Jul 2003 B1
6588902 Isogai Jul 2003 B2
6589280 Koziol Jul 2003 B1
6592621 Domino Jul 2003 B1
6596026 Gross et al. Jul 2003 B1
6599305 Feingold Jul 2003 B1
6607527 Ruiz et al. Aug 2003 B1
6607556 Nigam Aug 2003 B1
6613088 Babizhayev Sep 2003 B1
6614570 Johnson et al. Sep 2003 B2
6620634 Johnson et al. Sep 2003 B2
6623497 Feingold Sep 2003 B1
6623522 Nigam Sep 2003 B2
6624730 Johnson et al. Sep 2003 B2
6626941 Nigam Sep 2003 B2
6632244 Nigam Oct 2003 B1
6638304 Azar Oct 2003 B2
6663668 Chaouk et al. Dec 2003 B1
6669795 Johnson et al. Dec 2003 B2
6673112 Nigam Jan 2004 B2
6692126 Xie et al. Feb 2004 B1
6702807 Peyman Mar 2004 B2
6729599 Johnson May 2004 B2
6740116 Morcher May 2004 B2
6742761 Johnson et al. Jun 2004 B2
6746890 Gupta et al. Jun 2004 B2
6749632 Jethmalani et al. Jun 2004 B2
6755819 Waelti Jun 2004 B1
6755858 White Jun 2004 B1
D493889 Yoo Aug 2004 S
6786926 Peyman Sep 2004 B2
6790298 Johnson et al. Sep 2004 B2
6811256 Becherer et al. Nov 2004 B1
6813097 Jethmalani et al. Nov 2004 B2
6824266 Jethmalani et al. Nov 2004 B2
6849090 Nigam Feb 2005 B2
6851804 Jethmalani et al. Feb 2005 B2
6855163 Peyman Feb 2005 B2
6874886 Miller et al. Apr 2005 B2
6899424 Miller et al. May 2005 B2
6949093 Peyman Sep 2005 B1
6951556 Epstein Oct 2005 B2
6966648 Miller et al. Nov 2005 B2
6976997 Noolandi et al. Dec 2005 B2
6986763 Holmen Jan 2006 B2
6989008 Peyman Jan 2006 B2
7001374 Peyman Feb 2006 B2
7008447 Koziol Mar 2006 B2
7025455 Roffman Apr 2006 B2
7097649 Meyer Aug 2006 B2
7179292 Worst et al. Feb 2007 B2
7207998 Feingold Apr 2007 B2
7364674 Hoover Apr 2008 B1
D569512 Poll et al. May 2008 S
D571915 Poll et al. Jun 2008 S
7399811 Mentak et al. Jul 2008 B2
7404637 Miller et al. Jul 2008 B2
7404638 Miller et al. Jul 2008 B2
7446157 Mentak et al. Nov 2008 B2
7462194 Blake Dec 2008 B1
7491350 Silvestrini Feb 2009 B2
D589615 Doenges et al. Mar 2009 S
7628810 Christie et al. Dec 2009 B2
7645291 Ross et al. Jan 2010 B2
7645299 Koziol Jan 2010 B2
7745555 Mentak et al. Jun 2010 B2
7828844 Marmo et al. Nov 2010 B2
7976577 Silvestrini Jul 2011 B2
D645337 Hsu et al. Sep 2011 S
8048972 Mentak et al. Nov 2011 B2
8079706 Silvestrini et al. Dec 2011 B2
D656526 Christie et al. Mar 2012 S
8216765 Morimitsu et al. Jul 2012 B2
8287592 Silvestrini Oct 2012 B2
8343215 Miller et al. Jan 2013 B2
8349006 Zhao et al. Jan 2013 B2
D681086 Christie et al. Apr 2013 S
8420753 Mentak et al. Apr 2013 B2
8460374 Christie et al. Jun 2013 B2
8568478 Zickler et al. Oct 2013 B2
8604098 Boydston et al. Dec 2013 B2
8633292 Hu et al. Jan 2014 B2
8740978 Weeber et al. Jun 2014 B2
8752958 Miller et al. Jun 2014 B2
20010004702 Peyman Jun 2001 A1
20010027314 Peyman Oct 2001 A1
20010034516 Peyman Oct 2001 A1
20010047203 Dalton et al. Nov 2001 A1
20010050750 Breger Dec 2001 A1
20020010510 Silvestrini Jan 2002 A1
20020016629 Sandstedt et al. Feb 2002 A1
20020028330 Patel et al. Mar 2002 A1
20020029981 Nigam Mar 2002 A1
20020042004 Sandstedt et al. Apr 2002 A1
20020055753 Silvestrini May 2002 A1
20020057148 Johnson et al. May 2002 A1
20020075447 Andino et al. Jun 2002 A1
20020082288 Horn Jun 2002 A1
20020107337 Rosenzweig et al. Aug 2002 A1
20020107566 Nigam Aug 2002 A1
20020111677 Nigam Aug 2002 A1
20020120329 Lang et al. Aug 2002 A1
20020128710 Eggleston Sep 2002 A1
20020133228 Sarver Sep 2002 A1
20020138070 Peyman Sep 2002 A1
20020167640 Francis et al. Nov 2002 A1
20020167735 Jethmalani et al. Nov 2002 A1
20020169491 Foster et al. Nov 2002 A1
20020169505 Jethmalani et al. Nov 2002 A1
20020173846 Blake et al. Nov 2002 A1
20020187986 Horn Dec 2002 A1
20020188351 Laguette Dec 2002 A1
20020196409 Jani Dec 2002 A1
20030002994 Johnson et al. Jan 2003 A1
20030007122 Streibig Jan 2003 A1
20030014021 Holmen Jan 2003 A1
20030014042 Juhasz et al. Jan 2003 A1
20030014107 Reynard Jan 2003 A1
20030033013 Callahan et al. Feb 2003 A1
20030045930 Nguyen Mar 2003 A1
20030048411 Jethmalani et al. Mar 2003 A1
20030055497 Hicks et al. Mar 2003 A1
20030071893 Miller et al. Apr 2003 A1
20030078655 Callahan et al. Apr 2003 A1
20030088313 Nigam May 2003 A1
20030090013 Jethmalani et al. May 2003 A1
20030090624 Jethmalani et al. May 2003 A1
20030093083 Peyman May 2003 A1
20030093150 Jethmalani et al. May 2003 A1
20030105521 Perez Jun 2003 A1
20030115718 Bechthold Jun 2003 A1
20030127318 Johnson et al. Jul 2003 A1
20030128336 Jethmalani et al. Jul 2003 A1
20030151825 Bielawski et al. Aug 2003 A1
20030151831 Sandstedt et al. Aug 2003 A1
20030174375 Jethmalani et al. Sep 2003 A1
20030176521 Jethmalani et al. Sep 2003 A1
20030216763 Patel Nov 2003 A1
20030220653 Perez Nov 2003 A1
20040014253 Gupta et al. Jan 2004 A1
20040015234 Peyman Jan 2004 A1
20040019379 Glick et al. Jan 2004 A1
20040047014 Parker et al. Mar 2004 A1
20040049174 Peyman Mar 2004 A1
20040056371 Liao et al. Mar 2004 A1
20040068317 Knight Apr 2004 A1
20040078075 Koziol Apr 2004 A1
20040080239 Gupta et al. Apr 2004 A1
20040086479 Grinstaff et al. May 2004 A1
20040106929 Masket Jun 2004 A1
20040243231 Koziol Dec 2004 A1
20050027354 Brady et al. Feb 2005 A1
20050027355 Murakami Feb 2005 A1
20050031697 Vehige et al. Feb 2005 A1
20050033420 Christie et al. Feb 2005 A1
20050046794 Silvestrini et al. Mar 2005 A1
20050049621 Feingold et al. Mar 2005 A1
20050080485 Nigam Apr 2005 A1
20050090895 Peyman Apr 2005 A1
20050099597 Sandstedt et al. May 2005 A1
20050119738 Nigam Jun 2005 A1
20050124983 Frey et al. Jun 2005 A1
20050143717 Peyman Jun 2005 A1
20050143812 Paul et al. Jun 2005 A1
20050182488 Peyman Aug 2005 A1
20050187621 Brady Aug 2005 A1
20050222679 Peyman Oct 2005 A1
20050228376 Vannoy Oct 2005 A1
20050246015 Miller Nov 2005 A1
20050246016 Miller et al. Nov 2005 A1
20050246019 Blake et al. Nov 2005 A1
20060064077 Peyman Mar 2006 A1
20060079959 Christie et al. Apr 2006 A1
20060079960 Christie et al. Apr 2006 A1
20060095127 Feingold et al. May 2006 A1
20060098162 Bandhauer et al. May 2006 A1
20060113054 Silvestrini Jun 2006 A1
20060118263 Silvestrini Jun 2006 A1
20060184243 Yilmaz Aug 2006 A1
20060203192 Miller et al. Sep 2006 A1
20060235428 Silvestrini Oct 2006 A1
20060241751 Marmo et al. Oct 2006 A1
20060252844 Mentak Nov 2006 A1
20060265058 Silvestrini Nov 2006 A1
20060268226 Christie et al. Nov 2006 A1
20060268227 Christie et al. Nov 2006 A1
20060268228 Christie et al. Nov 2006 A1
20060268229 Silvestrini et al. Nov 2006 A1
20060270946 Silvestrini et al. Nov 2006 A1
20060271026 Silvestrini et al. Nov 2006 A1
20060271027 Silvestrini et al. Nov 2006 A1
20060271176 Christie et al. Nov 2006 A1
20060271177 Christie et al. Nov 2006 A1
20060271178 Christie et al. Nov 2006 A1
20060271179 Christie et al. Nov 2006 A1
20060271180 Christie et al. Nov 2006 A1
20060271181 Christie et al. Nov 2006 A1
20060271182 Christie et al. Nov 2006 A1
20060271183 Christie et al. Nov 2006 A1
20060271184 Silvestrini Nov 2006 A1
20060271185 Silvestrini Nov 2006 A1
20060274264 Christie et al. Dec 2006 A1
20060274265 Christie et al. Dec 2006 A1
20070016234 Daxer Jan 2007 A1
20070129797 Lang et al. Jun 2007 A1
20070219542 Yahagi Sep 2007 A1
20070225691 Silvestrini et al. Sep 2007 A1
20080033546 Liang Feb 2008 A1
20080077238 Deacon et al. Mar 2008 A1
20080125862 Blake May 2008 A1
20080151183 Altmann Jun 2008 A1
20080212030 Bentley et al. Sep 2008 A1
20080275462 Feingold Nov 2008 A1
20090012505 Chernyak Jan 2009 A1
20090059168 Miller et al. Mar 2009 A1
20090069817 Peyman Mar 2009 A1
20090204207 Blum et al. Aug 2009 A1
20090222086 Lui et al. Sep 2009 A1
20090306773 Silvestrini et al. Dec 2009 A1
20100234942 Peyman Sep 2010 A1
20100312336 Hong et al. Dec 2010 A1
20110040376 Christie et al. Feb 2011 A1
20110172675 Danta et al. Jul 2011 A1
20110245818 Weinschenk, III Oct 2011 A1
20110245919 Pettit Oct 2011 A1
20120143325 Christie et al. Jun 2012 A1
20120203239 Vukich et al. Aug 2012 A1
20120245683 Christie et al. Sep 2012 A1
20120309761 Chow et al. Dec 2012 A1
20120310338 Christie et al. Dec 2012 A1
20130053953 Silvestrini Feb 2013 A1
20130103147 Christie et al. Apr 2013 A1
20130131795 Miller et al. May 2013 A1
20130238091 Danta et al. Sep 2013 A1
20130268071 Vilupuru et al. Oct 2013 A1
20140131905 Webb May 2014 A1
Foreign Referenced Citations (178)
Number Date Country
241 330 Dec 1992 AR
241 830 Dec 1992 AR
244 890 Nov 1993 AR
739297 Jan 2002 AU
0772492 Aug 2004 AU
778310 Mar 2005 AU
2003252004 Mar 2010 AU
2006236715 Jun 2012 AU
0008601 Dec 2001 BR
0008624 Dec 2001 BR
PI-9809289-8 Dec 2006 BR
2286718 Nov 2008 CA
1253484 May 2000 CN
1875895 Dec 2006 CN
101198294 Jun 2008 CN
101198364 Jun 2008 CN
101322663 Dec 2008 CN
102448404 May 2012 CN
102470033 May 2012 CN
3433581 Mar 1986 DE
41 34 320 Apr 1992 DE
0165652 Dec 1985 EP
0225098 Jun 1987 EP
0286433 Oct 1988 EP
0443094 Aug 1991 EP
0457553 Nov 1991 EP
0941717 Sep 1999 EP
1014872 Jul 2000 EP
1173790 Jan 2002 EP
1267998 Jan 2003 EP
1381326 Jan 2004 EP
1871298 Apr 2006 EP
1159033 Jan 2007 EP
1827330 Sep 2007 EP
1845896 Oct 2007 EP
1890736 Feb 2008 EP
1158936 Jul 2008 EP
1997530 Dec 2008 EP
1534188 Sep 2010 EP
2258311 Dec 2010 EP
2301477 Mar 2011 EP
1635739 Sep 2011 EP
2464310 Jun 2012 EP
2464311 Jun 2012 EP
2506803 Oct 2012 EP
369 993 Jan 1907 FR
1115140 Dec 1955 FR
1400566 Apr 1965 FR
2599156 May 1986 FR
2620687 Mar 1989 FR
2649605 Jan 1991 FR
1 026 839 Apr 1966 GB
1276003 Jun 1972 GB
1 547 525 Jun 1979 GB
2242835 Oct 1991 GB
1028531 Feb 2011 HK
1151451 Feb 2012 HK
11553484 May 2012 HK
1166457 Nov 2012 HK
1169935 Feb 2013 HK
62167343 Jul 1987 JP
63-17096 Apr 1988 JP
64-002644 Jan 1989 JP
1990-7954 Jan 1990 JP
03-001857 Jan 1991 JP
04-158859 Jun 1992 JP
04-223425 Aug 1992 JP
06-509731 Mar 1993 JP
H05-65340 Sep 1993 JP
6-502782 Mar 1994 JP
6-509731 Nov 1994 JP
07-050242 Feb 1995 JP
07-178125 Jul 1995 JP
07-265340 Oct 1995 JP
08-103457 Apr 1996 JP
09-502542 Mar 1997 JP
11-503657 Aug 1997 JP
2002-14772 Jan 2002 JP
2003-527228 Sep 2003 JP
2004-510199 Apr 2004 JP
2004-538034 Dec 2004 JP
2005-533576 Nov 2005 JP
2007-516019 Jun 2007 JP
2007-523720 Aug 2007 JP
4114036 Apr 2008 JP
2008-517671 May 2008 JP
2008-536574 Sep 2008 JP
2008-536576 Sep 2008 JP
4182390 Sep 2008 JP
2010-227615 Oct 2010 JP
2010-126600 Feb 2011 JP
4676761 Feb 2011 JP
4689615 Feb 2011 JP
4746052 May 2011 JP
10-0335722 May 2002 KR
600210 Jul 2006 KR
1008759 Jul 2003 MX
226369 Feb 2005 MX
227913 Mar 2006 MX
562987 Feb 2010 NZ
1380743 Mar 1998 RU
2138837 Sep 1999 RU
68726 Feb 2002 SG
83306 Feb 2004 SG
83307 Jul 2004 SG
200716909-7 Mar 2011 SG
WO 8705797 Oct 1987 WO
WO 8707165 Dec 1987 WO
WO 9116865 Nov 1991 WO
WO 9205694 Apr 1992 WO
WO 9303776 Mar 1993 WO
WO 9308878 May 1993 WO
WO 9312735 Jul 1993 WO
WO 9320763 Oct 1993 WO
WO 9401058 Jan 1994 WO
WO 9405232 Mar 1994 WO
WO 9423327 Oct 1994 WO
WO 9502356 Jan 1995 WO
WO 9503747 Feb 1995 WO
WO 9508135 Mar 1995 WO
WO 9635397 Nov 1996 WO
WO 9728759 Aug 1997 WO
WO 9748004 Dec 1997 WO
WO 9748005 Dec 1997 WO
WO 9827896 Jul 1998 WO
WO 9848715 Nov 1998 WO
WO 9907309 Feb 1999 WO
WO 0025704 May 2000 WO
WO 0038594 Jul 2000 WO
WO 0051682 Sep 2000 WO
WO 0052516 Sep 2000 WO
WO 0110641 Feb 2001 WO
WO 0115779 Mar 2001 WO
WO 0117460 Mar 2001 WO
WO 0119364 Mar 2001 WO
WO 0182815 Nov 2001 WO
WO 0187189 Nov 2001 WO
WO 0213881 Feb 2002 WO
WO 0227388 Apr 2002 WO
WO 02076320 Oct 2002 WO
WO 02102241 Dec 2002 WO
WO 03020177 Mar 2003 WO
WO 03022168 Mar 2003 WO
WO 03030763 Apr 2003 WO
WO 03061518 Jul 2003 WO
WO 2004014969 Feb 2004 WO
WO 2004034917 Apr 2004 WO
WO 2004050132 Jun 2004 WO
WO 2004105588 Dec 2004 WO
WO 2004105588 Dec 2004 WO
WO 2005033263 Apr 2005 WO
WO 2005082265 Sep 2005 WO
WO 2006020638 Feb 2006 WO
WO 2006047534 May 2006 WO
WO 2006047698 May 2006 WO
WO 2006060380 Jun 2006 WO
WO 2006113377 Oct 2006 WO
WO 2006113411 Oct 2006 WO
WO 2006113474 Oct 2006 WO
WO 2006113563 Oct 2006 WO
WO 2006113564 Oct 2006 WO
WO 2007057734 May 2007 WO
WO 2007057734 Oct 2007 WO
WO 2007142981 Dec 2007 WO
WO 2008036671 Mar 2008 WO
WO 2008102096 Aug 2008 WO
WO 2008121649 Oct 2008 WO
WO 2009050511 Apr 2009 WO
WO 2009122409 Oct 2009 WO
WO 2009149060 Dec 2009 WO
WO 2011020074 Feb 2011 WO
WO 2011020078 Feb 2011 WO
WO 2011047076 Apr 2011 WO
WO 2011069059 Jun 2011 WO
WO 2011088107 Jul 2011 WO
WO 2013082545 Jun 2013 WO
WO 2013123265 Aug 2013 WO
WO 2014074610 May 2014 WO
Non-Patent Literature Citations (126)
Entry
Accomodation and acuity under night-driving illumination levels. Arumi et al. Ophthal. Physiol. Opt. vol. 17, No. 4, pp. 291-299, 1997.
Accommodation and Presbyopia. Croft et al., International Opthalmology Clinics: Spring 2001, vol. 41, Issue 2, pp. 33-46.
Accomodation dynamics as a function of age. Heron et al. Ophthal. Physiol. Opt. 2002 22:389-396.
Accommodation Responses and Ageing. Heron et al. IOVS, Nov. 1999, vol. 40, No. 12, pp. 2872-2883.
Accommodative responses to anisoaccommodative targets. Koh et al. Ophthal. Physiol. Opt. vol. 18, No. 3, pp. 254-262, 1998.
Accommodation responses to flickering stimuli. Chauhan et al. Ophthal. Physiol. Opt. vol. 16. No. 5, pp. 391-408, 1996.
Accommodation to perceived depth in stereo tests. Koh et al. Ophthal. Physiol. Opt. vol. 18, No. 3, pp. 279-284, 1998.
Age Changes in the Interactions between the Accommodation and Vergence Systems. Heron et al. Optometry and Vision Science. vol. 78, No. 10, Oct. 2001.
Anterior Ciliary Sclerotomy for Treatment of Presbyopia: A Prospective Controlled Study. Hamilton et al. Ophthalmology, vol. 109, No. 11: Nov. 2002: pp. 1970-1977.
Barraquer, “Keratomileusis for Myopia and Aphakia”, Ophthalmology, Rochester 88:701-708, 1981.
Binder et al., “Hydrogel keratophakia in non-human primates”, Current Eye Research, vol. 1, No. 9, 1981/1982, pp. 535-542.
Brooks, J. et al., Identification of a vimentin-reactive Peptide associated with ocular lens membranes as cytokeratin, Ophthalmic Res., Jan.-Feb. 2003, pp. 8-11, vol. 35.
Cao et al, “Comparative study of the use of poly(glycolic acid), calcium alginate and pluronics in the engineering of autologous porcine cartilage”, Polymers for Tissue Engineering, pp. 315-327, VSP 1998.
Can Accommodation be Surgically Restored in Human Presbyopia? Glasser, Adrian. Optometry and Vision Science, vol. 76, No. 9, Sep. 1999.
Changes in the static accommodation response with age. Kalsi et al. Ophthal. Physiol. Opt. vol. 21, No. 1, pp. 77-84, 2001.
Choice of Spatial Frequency for Contrast Sensitivity Evaluation After Corneal Refractive Surgery. Montes-Mico et al. Journal of Refractive Surgery, vol. 17: Nov./Dec. 2001: pp. 646-651.
Chow, C., et al., Broadband optical ultrasound sensor with a unique open-cavity structure, J. Biomed. Opt., Jan.-Feb. 2011, pp. 017001, vol. 16.
Choyce, P. “Implants with Coloured and Opaque Portions: Implants with Built-In Stenopeic Aperture,” pp. 21-26 “Uniocular Aphakia Corrected by Anterior Chamber Implants with Built-In Stenopeic Aperture,” pp. 132-136, 1964.
Clinical Characteristics of Lamellar Channel Deposits After Implementation of Intacs. Ruckhofer et al. J Cataract Refract Surg, vol. 26, Oct. 2000: pp. 1473-1479.
Contemporary Polymer Applications for Corneal Surgery. McCarey, Bernard E. pp. 504-505.
Cotliar et al., “Excimer Laser Radial Keratotomy”, Ophthalmology, 1985.
Corneal Topography: The State of the Art, Alignment of Videokeratographs. Mandell et al. Chpt. 2, pp. 17-23, Jan. 1995.
“Corneal Surgery” by L. Girard, The C.V. Mosby Publishing Company, London 1981 pp. 107-141.
Dynamics of the accommodation response to abrupt changes in target vergence as a function of age. Heron et al. Vision Research 41 (2001) 507-519.
Dynamic retinoscopy and accomodation. Whitefoot et al. Ophthal. Physiol. Opt. vol. 12, Jan. 1992, pp. 8-17.
Eduard Jaeger's Test-Types (Schrift-Scalen) and Historical Development of Vision Tests. Runge, Paul E. Tr. Am. Ophth. Soc. vol. 98, 2000: 375.
Eight Years Experience with Permalens Intracorneal Lenses in Nonhuman Primates. Werblin et al. Refractive & Corneal Surgery, vol. 8, Jan./Feb. 1992, pp. 12-21.
“Epikeratophakia: Techniques, Compositions, and Clinical Results” by Werblin, Ophthalmology, 1983, pp. 45-58.
Errors in determining the direction of the visual axis in the presence of defocus. Atchison et al. Ophthal. Physiol. Opt., vol. 18, No. 5, pp. 463-467, 1998.
Evaluate surgical routine to determine DLK cause, surgeon advises. Piechocki, Michael. Ocular Surgery News: Refractive Surgery, Jan. 1, 2003: p. 14.
Explanation for the observation of isogyres in crystalline lenses viewed between crossed polarizers. Ophthal. Physiol. Opt., vol. 13, Apr. 1993, pp. 209-211.
FDA Summary of Safety and Effectiveness Data for Tecnis Multifocal Posterior Chamber Intraocular Lens, Models ZM900 and ZMA00, 2009.
FDA Summary of Safety and Effectiveness Data for the Advanced Vision Science, Inc. XACT Foldable Hydrophopic Acrylic Ultraviolet Light-Absorving Posterior Chamber Intraocular Lens (Model X-60 and Model X-70), 2009.
FDA Summary of Safety and Effectiveness Data for EC-3 IOL, (Models EC-3 IOL and EC-3 Precision Aspheric Lens), 2010.
FDA Summary of Safety and Effectiveness Data for Aaren Scientific's EC-3 IOL, 2010.
FDA Summary of Safety and Effectiveness Data for XACT Foldable Hydrophopic Acrylic UV Absorving Posterior Chamber Intraocular Lens discussing clinical investigation beginning on May 8, 2002.
Flap Measurements With the Hansatome Microkeratome. Spadea et al. Journal of Refractive Surgery, vol. 18, Mar./Apr. 2002: pp. 149-154.
Focused and divided attention in stereoscopic depth. Wickens et al. SPIE, vol. 1256 Stereoscopic Displays and Applications (1990); pp. 28-34.
Gamez, G., et al., Development of a pulsed radio frequency glow discharge for three-dimensional elemental surface imaging. 1. Application to biopolymer analysis, Anal. Chem., Feb. 2007, pp. 1317-1326, vol. 79.
Glasier, M., et al., A solid-phase assay for the quantitation of total protein eluted from balafilcon, lotrafilcon, and etafilcon contact lenses, Current Eye Research, 2008, pp. 631-640, vol. 33.
Griffith et al.; “Functional Human Corneal Equivalents Constructed from Cell Lines”, Science, vol. 286, Dec. 10, 1999 pp. 2169-2172.
Groppi, J. J. “New Aspects in the Fitting of the Multi-Range Bifocal Contact Lens” Contacto, vol. 15:22-29 1971.
Hara, T., et al., Accommodative intraocular lens with spring action. Part 1. Design and placement in an excised animal eye, Ophthalmic Surg., Feb. 1990, vol. 21.
Hara, T., et al., Ten-year results of anterior chamber fixation of the posterior chamber intraocular lens, Arch. Ophthalmol., Aug. 2004, pp. 1112-1116.
Hayasaka, S., et al., Scanning electron microscopic study of polyvinylidene fluoride degradation by ocular tissue extracts, Jpn. J. Ophthalmol., 1984, pp. 131-135, vol. 28.
Hayashi, K., et al., Intraocular lens factors that may affect anterior capsule contraction, Ophthalmology, Feb. 2005, pp. 286-292, vol. 112.
Hayashi, K., et al., Comparison of decentration and tilt between one piece and three piece polymethyl methacrylate intraocular lenses, Br. J. Ophthalmol., Apr. 1998, pp. 419-422, vol. 82.
Hidaka, T., et al, Adaptive optics instrumentation in submillimeter/terahertz spectroscopy with a flexible polyvinylidene fluoride cladding hollow waveguide, Rev. Sci. Instrum., 2007, pp. 25-26, vol. 78.
Hoffer et al., “UCLA Clinical Trial of Radial Keratotomy” Opthalmology, Aug. 1981; 88:729-736.
Holes in Clear Lenses Demonstrate a Pinhole Effect. Zacharia et al. Arch Ophthalmol, vol. 106, Apr. 1988, pp. 511-513.
Human Visual System—Image Formation, Encyclopedia of Imaging Science and Technology, Roorda, A., 2002, pp. 539-557.
Hybrid diffractive-refractive achromatic spectacle lenses. Charman, W. N. Ophthal. Physiol. Opt., vol. 14, Oct. 1994: pp. 389-392.
Iijima et al. “Formation of a spherical multicellular aggregate (spheroid) of animal cells in the pores of polyurethane foam as a cell culture substratum and its application to a hybrid artificial liver”, Polymers for Tissue Engineering , pp. 273-286, VSP 1998.
Imaging in the 21st century. Charman, W. N. Ophthal. Physiol. Opt., vol. 18, No. 2, pp. 210-223,1998.
Intra-Ocular Lenses and Implants. Choyce, Peter. Chpts.4 & 17, 1964.
Intraocular pressure after excimer laser myopic refractive surgery. Montes-Mico et al. Ophthal. Physiol. Opt., vol. 21, No. 3, pp. 228-235, 2001.
Intrastromal Crystalline Deposits Following Hydrogel Keratophakia in Monkeys. Parks et al. Cornea, 12(1): 29-34, 1993.
Izak, A., et al., Loop memory of haptic materials in posterior chamber intraocular lenses, J. Cataract Refract. Surg., Jul. 2002, pp. 1129-1135, vol. 28.
“Katena Eye Instruments Catalog—Blaydes” dated Feb. 22, 2010, obtained from the Internet at: www.katena.com/html/product—detail.cfm in 1 page and printed on Feb. 22, 2010.
Kenyon. “Recurrent Corneal Erosion: Pathogenesis and Therapy,” 1978, pp. 169-195.
“Keratomileusis and Keratophakia in the Surgical Correction of Aphakia” by Barraquer, Cataract Surgery and Special Techniques, prior to 1996 pp. 270-289.
Khodadoust et al., “Adhesion of Regenerating Corneal Epithelium,” Am. J. of Opthalmology, Mar. 1968, pp. 339-348.
Kimura, W., et al., Comparison of shape recovery ratios in various IOL haptics, Nippon Ganka Gakkai Zasshi, Jun. 1991, pp. 548-555, vol. 95.
Kimura, W., et al., Comparison of shape recovery ratios in various intraocular lens haptics, J. Cataract. Refract. Surg., Nov. 1992, pp. 547-553, vol. 18.
Kimura, W., et al., Comparison of shape recovery ratios of single-piece poly(methyl methacrylate) intraocular lens haptics., J. Cataract. Refract. Surg., Sep. 1993, pp. 635-639, vol. 19.
Ko, A., et al., Seroreactivity against aqueous-soluble and detergent-soluble retinal proteins in posterior uveitis, Arch. Ophthalmol., Apr. 2011, pp. 415-420, vol. 129.
Kocak, N., et al., Intraocular lens haptic fracturing with the neodymium: YAG laser in vitro study, J. Cataract Refract. Surg., Apr. 2006, pp. 662-665, vol. 32.
Kruusing, A. Underwater and water-assisted laser processing: Part 2—Etching, cutting and rarely used methods. Optics and Lasers in Engineering, 2004: pp. 329-352.
“Lamellar Corneal Stromectomy for the Operative Treatment of Myopia” by Tadeusz Krwawicz, Notes, Cases, Instruments—1964, pp. 828-833.
Lipid Deposits Posterior to Impermeable Intracorneal Lenses in Rhesus Monkeys: Clinical, Histochemical, and Ultrastructural Studies. Rodrigues et al. Refractive & Corneal Surgery, vol. 6, Jan./Feb. 1990: DO. 32-37.
Lu Xuequan. Zhai Madlin, Li Jiuqiang, Ha Hongfei: “Radiation preparation and thermo-response swelling of interpenetrating polymer network hydrogel composed of PNIPAAm and PMMA” Radiation Physics and Chemistry, vol. 57, 2000, pp. 477-480, XP002473596.
Mastel Precision: Fiber Optic Ring Illuminator (Product Nos. 3776 & 4050) U.S. Pat. No. 5312393, User Manual. Rev: A02: Jan. 11, 1995, pp. 1-25.
Mastel Precision: The Ring Light. http://www.mastel.com/ring—light.html. Jul. 28, 2003.
Measurement of the wave-front aberration of the eye by a fast psychophysical procedure. He et al. J. Opt. Soc. Am. A, vol. 15, No. 9: Sep. 1998, pp. 2449-2455.
Microstructural Changes in Polyester Biotextiles During Implantation in Humans. King et al. NC State University: JTATM, vol. 1, Issue 3, Spring 2001, pp. 1-8.
Miller et al. “Quantification of the Pinhole effect” Perspectives in Refraction, vol. 21:347-350 1977.
Moran, C., et al. Polyvinylidene flouride polymer applied in an intraocular pressure sensor, Jpn. J. Appl. Phys., 2005, pp. L885-L887, vol. 44, Issue 27.
Near vision, lags of accommodation and myopia. Charman, W. N. Ophthal. Physiol. Opt., vol. 19, No. 2, pp. 126-133, 1999.
New Visual Acuity Charts for Clinical Research. Ferris et al. American Journal of Ophthalmology, 94: 91-96, 1982.
Night myopia and driving. Charman, W. N. Ophthal. Physiol. Opt., vol. 16, No. 6, p. 474-485, 1996.
Notch in contrast sensitivity function of optical origin: diffraction effects of acrylic filters. Irving et al., Ophthal. Physiol. Opt., vol. 13, Apr. 1993: pp. 179-182.
On modeling the causes of presbyopia. Glasser, A. Vision Research 41(2001) 3083-3087.
On the linearity of accommodation dynamics. Charman, W. N. Vision Research 40 (2000) 2057-2066.
Optical Aspects of Tolerances to Uncorrected Ocular Astigmatism. Charman et al. Optometry and Vision Science, vol. 70, No. 2: pp. 111-117, 1993.
Optical Modeling of Contact Lens Performance Final Report Covering Period Jul. 15, 1994-Mar. 31, 1995. Grivenkamp et al. For Pilkington Barnes Hind, Issued Apr. 5, 1995.
Optometric Clinical Practice Guideline Care of the Patient With Presbyopia: Reference Guide for Clinicians. Mancil et al. Mar. 20, 1998.
Ozanics et al., “Prenatal Development of the Eye and its Adnexa,” Biomedical Foundation of Opthalmology, 1985, vol. 1, Chap 2, pp. 7-15.
Patel, C.K., et al. “Imaging the macula through a black occlusive intraocular lens”. Arch. Ophthalmol. Oct. 2010; 128(10):1374-1376.
PermaVision intracorneal lens shows promise for hyperopia. Kronemyer, Bob. Ocular Surgery News: Jan. 1, 2003; p. 8.
Perspectives in Refraction: Quantification of the Pinhole Effect. Miller et al. Survey of Ophthalmology, vol. 21, No. 4, Jan./Feb. 1977, pp. 347-350.
Peyman et al., “Modification of Rabbit Corneal Curvature with use of Carbon Dioxide Laser Burns,” Ophth, Surg., vol. 11, No. 5, 5/80, pp. 325-329.
Puliafito, C., et al., “Excimer Laser Ablator of the Cornea & Lens,” Opthalmology, 6/85 vol. 92 No. 6, pp. 741-748.
Sally Pobojewski, “New U-developed laser performs high-precision corneal surgery”, News and Information Services, The University Record, Jul. 16, 1997.
Poly(methyl methacrylate) model study of optical surface quality after excimer laser photo refractive keratectomy. Hauge et al. J Cataract Refract Surg., vol. 27, Dec. 2001, pp. 2026-2035.
Prince, S., et al., Sorption of alkylbenzyldimethylammonium chloride homologs to various filter media used in processing ophthalmics, APhA Annual Meeting, 1996, pp. 103, vol. 143.
Procyon: Marketing Information for Distributors: Pupil Measurement and Refractive Surgery (Samples from Academic Papers 1994 and 2002). pp. 1-17.
“Refractive Keratoplasty: Acute Morphologic Features,” by Baumgarter et al, The CLAO Journal—Apr. 1985, vol. II, No. 2, pp. 163-169.
Refractive keratoplasty with intrastromal hydrogel lenticular implants. McCarey et al. Invest., Ophthalmol. Vis. ScL, Jul. 1981, pp. 107-115.
Retinal Image Quality in the Human Eye as a Function of the Accommodation. Lopex-Gil et al. Vision Research, vol. 38, No. 19,Jul. 3, 1998, pp. 1-11.
Rosenbloom “The Controlled-Pupil Contact Lens in Low Vision Problems” Journal of the American Optometric Association, pp. 836, 838, 840 1969.
Sato, “A New Surgical Approach to Myopia”, Am. J. Ophthalmol. 36:823, 1953.
Shingleton, B., Reply: pupil stretch technique, J. Cataract Refract. Surg., 2007, pp. 362, vol. 33.
Simple parametric model of the human ocular modulation transfer function, A. Deeley et al. Ophthal. Physiol. Opt., vol. 11, Jan. 1991, pp. 91-93.
Karin R. Slettin, MD et al., “An In Vivo Model of Femtosecond Laser Intrastromal Refractive Surgery”, Experimental Science, Ophthalmic Surgery and Lasers, Nov./Dec. 1999, vol. 30, No. 9, pp. 742-749.
Subjective Depth-of-Focus of the Eye. Atchison et al. Optometry and Vision Science, vol. 74, No. 7, Jul. 1997, pp. 511-520.
Subjective Sensitivity to Small Changes in the Contrast of a Suprathreshold Grating, The. Walsh et al. Vision Res., vol. 30, No. 1, pp. 163-193, 1990.
Surface Modification Properties of Parylene for Medical Applications, The. Wolgemuth, Lonny.Business Briefing: Medical Device Manfacturing & Technology 2002, pp. 1-4.
Surface tension control of collagen biomaterials by the selective hydrolysis of internal carboxyamides of the protein matrix. Revista Brasileira de Engenharia Biomedica, v. 15, n. 1-2, p. 55-61, Jan./Aug. 1999.
Surgeon: Severe corneal lesions after LASIK are not stage 4 DLK. Piechocki, Michael. Ocular SurgeryNews; Jan. 1, 2003, pp. 16-17.
Subrayan, V., et al., Improving quality of vision with an anterior surface modified prolate intraocular lens: A prosepective clinical trial, Int. J. Ophthalmol., Aug. 2007, pp. 918-920, vol. 7, No. 4.
Swinger et al., “Keratophakia and Keratomileusis—Clinical Results”, American Academy of Ophthalmology, Aug. 1981, vol. 88, No. 8, pp. 709-715.
Taboda, J., et al., “Response of the Corneal Epithelium to K.F. Excimer Laser Pulses,” Health Physics, 1981, vol. 40, pp. 677-683.
Takahashi, E. “Use and Interpretation of the Pinhole Test” The Optometric Weekly, pp. 83-86 1965.
Tasaki, I., et al., Demonstration of heat production associated with spreading depression in the amphibian retina, Biochem. Biophys. Res. Commun., 1991, pp. 293-297, vol. 174.
Theoretical and practical performance of a concentric bifocal intraocular implant lens. Charman, W.N. Vision Research 38 (1998) 2841-2853.
Trokel, S., et al., “Excimer Laser Surgery of the Cornea,” Am. J. Opthalmology, 1983 vol. 96, pp. 710-715.
Use of a digital infrared pupillometer to assess patient suitability for refractive surgery. Rosen et al. J Cataract Refract Surg., vol. 28: Aug. 2002. pp. 1433-1438.
Vision and driving—a literature review and commentary. Charman, W.N. Ophthal. Physiol. Opt., vol. 17, No. 5, pp. 371-391, 1997.
Wesley, N. K. “Research on the Multi-Range Lens,” pp. 18-24, 1970.
Yamauchi et al., “Cultivation of fibroblast cells on keratin coated substrata”, Polymers for Tissue Engineering, pp. 329-340, VS 1998.
Yusuf, et al., “Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use”, J. Cataract Refract. Surg., Mar. 2012, 38: 513-513.
Yusuf, et al., “Occlusive IOLs for Intractable Diplopia Demonstrate a Novel Near-Infrared Window of Transmission for SLO/OCT Imaging and Clinical Assessment”. Investigative Ophthalmology & Visual Science, May 2011, 52(6): 3737-3743.
Zavala et al., “Refractive Keratoplosty: Lathing and Cyropreservation,” CLAO Journal, Apr. 1985, 11:155-162.
Guyton A.C., Textbook of Medical Physiology, 7th Edition, W.B. Saunders Company, 1986: Chapter 58, pp. 700-710.
International Search Report and Written Opinion for PCT/US2010/045541 mailed Oct. 12, 2010 in 11 pages.
International Search Report and Written Opinion for PCT/US2014/020252 mailed Jul. 7, 2014 in 16 pages.
Related Publications (1)
Number Date Country
20140277432 A1 Sep 2014 US